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ABSTRACT
HUMAN GONADOTROPIN-RELEASING HORMONE (hGnRH) GENE
EXPRESSION AND HORMONE REGULATION IN HUMAN PLACENTAL
JEG-3 CELLS
Heming Zheng
Eastern Virginia Medical School And Old Dominion University, 2000
Director: Dr. Ke-Wen Dong
Using the human placental choriocarcinoma JEG-3 cel! line as an in vitro 
human placental model, I studied the mechanisms of the tissue-specific 
expression and steroid hormone regulation of the hGnRH gene in the human 
placenta. The results showed that all of the previously identified four elements 
are required for the full activity of the hGnRH upstream promoter in JEG-3 cells, 
while the element 4 (FP4, -987/-968) is the most important. Studies performed 
with 5’ end deletion of this region confirmed these observations. Further, 
supershift assay using Oct-1 antibody demonstrated the involvement of Oct-1 in 
the FP4 DNA-protein interaction in JEG-3 cells.
Transient transfection studies showed that hERa and hERp mediate inhibitory 
effects of estradiol on the hGnRH upstream promoter in JEG-3 cells in a 
receptor-mediated and dose-dependent manner, while hERp acts to a lesser 
extent than hERa. Also, hERa and hERp exhibit distinctive actions in directing 
the effects of estrone, estradiol, and estriol on the upstream promoter.
Furthermore, mutagenesis studies confirmed the negative (-991 to -935) and 
positive (-827 to -730) estrogen responsive elements in the hGnRH upstream 
promoter. However, gel shift assay using hERa protein did not cause any
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
shifting, suggesting that ER may not be directly involved in the DNA-protein 
binding.
In addition, progesterone exhibited a stimulatory effect on the hGnRH 
upstream promoter activity in JEG-3 in a receptor-mediated and dose-dependent 
manner. PR-B mediated a more potent stimulatory effect than PR-A. Moreover, 
exogenous expressions of coactivators SRC-1 and CBP, independently and 
synergistically, upregulated the PR-A and PR-B mediated progesterone effects 
on the hGnRH upstream promoter in JEG-3 cells.
Taken together, multiple cis-regulatory elements and trans-acting factors 
involved in the regulation of the hGnRH upstream promoter activity in JEG-3 
cells. Different steroid hormone receptor isoforms mediate distinctive effects on 
the hGnRH upstream promoter activities. Although several hormone responsive 
elements have been confirmed, there is no evidence for direct binding of 
hormone receptors with the upstream promoter. Further studies are needed to 
identify the trans-regulatory proteins important for the expression and regulation 
of the hGnRH gene in the placental cells.
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1INTRODUCTION
Gonadotropin-releasing hormone (GnRH) is the hypothalamic-releasing factor 
that controls the biosynthesis of the pituitary gonadotropin subunits and, 
ultimately, reproductive competence. Generally, GnRH is produced in the 
hypothalamic neurons and secreted into the hypophysioportal circulation. At the 
level of the pituitary, GnRH acts through its receptor to stimulate the synthesis of 
the a  subunit, LH p subunit, FSH p subunit genes in the gonadotrophs. The 
biologically active dimmers LH and FSH are then secreted in a pulsatile manner 
into the peripheral circulation and control both gametogenesis and 
steroidogenesis in the gonad. In addition, GnRH may serve an important role in 
mediating sexual behavior directly through GnRH neurons in the brain and/or 
indirectly through the stimulation of gonadotrophins that subsequently affect 
target organs. During the past decades, the studies in understanding the function 
and regulation of GnRH have been primarily concentrated in the hypothalamus. It 
has been demonstrated that GnRH is regulated by gonadal steroids and 
peptides, neurotransmitters, other hypothalamic-releasing factors, and growth 
factors in the hypothalamus.
However, the expressions of GnRH gene and GnRH receptor gene have also 
been demonstrated in non-neural tissues, especially in reproductive tissues. The 
immunoreactive GnRH has been found in ovary (Aten et al., 1987), testes
The model journal used for this dissertation was Molecular and Cellular Endocrinology.
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2(Bhasin et al., 1983), mammary gland (Seppala et al., 1980), and placenta 
(Petraglia et al., 1990). The GnRH receptor-binding activity has also been 
demonstrated in the ovary (Latouche et al., 1989; Koves et al., 1989), mammary 
gland (Eiden et al., 1987), and placenta (Currie et al., 1989). These data together 
with the demonstration of the presence of GnRH mRNA (Dong et al., 1993; Ikeda 
et al., 1996 and 1997) and GnRH receptor mRNA (Peng et al., 1994; Lin et al., 
1995; Minaretzis et al., 1995) in reproductive tissues strongly indicate that GnRH 
and GnRH receptor are produced locally in reproductive tissues and act as a 
local regulatory factor. Therefore, in addition to the classic endocrine function, 
GnRH may act as an autocrine and/or paracrine factor in local regulation of 
reproductive functions. It has been found that GnRH exerts multiple extrapituitary 
actions (Hsueh and Jones, 1981) on reproductive tissues and directly modulate 
reproductive functions (Hsueh and Erichson, 1979; Hilensjo and Lemaire, 1980; 
Huseh et al., 1988) through GnRH receptor present in these tissues (Jones et al., 
1980; Piper et al., 1981). In the hypophysectomized rat, the action of GnRH in 
the ovary has been suggested to exert in an autocrine or paracrine manner, and 
treatment with high concentration of GnRH induces ovarian oocyte maturation 
(Aaron et al., 1985). GnRH also acts directly at the ovary to alter basal, as well 
as LH- and FSH-induced, steroidogenesis (Olsson et al., 1990; Bussenot et al., 
1993; Peng et al., 1994). Some studies on reproductive cancer cell lines have 
demonstrated that GnRH analogs can exert direct antiproliferative effects in vitro 
(Emons et al., 1993; Keri et al., 1992; Baumann et al., 1993). All these data
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
3support the role of GnRH as an autocrine amd/or paracrine factor in local 
regulation function in reproductive tissues.
Human placenta is a unique organ that serwes to transmit nutrients to the 
fetus and waste products from the fetus to the maternal circulation. The placenta 
also exerts hormonal modulation of maternal metabolism at different stages of 
gestation. The functional unit of the placenta is t f ie  chorionic villus, which has a 
central core of capillary network for the fetal circulation surrounded by the inner 
syncytiotrophoblast and outer cytoirophoblast. A  plethora of data indicate that in 
addition to the pituitary trophic hormone (such as the placental proteins -  human 
chorionic gonadotropin [hCG], human chorionic somatomammotropin [hCS], and 
human chorionic corticotropin [hCC]), hypothalaimic peptides, including GnRH, 
corticotropin-releasing hormone (CRH), and somatostatin, are also synthesized 
by trophoblastic cells. Furthermore, the presence of many of the growth factors 
and their receptors, as well as the inhibin family of gonadal peptides has been 
demonstrated as well. Taken together, the endogenous placental regulation of its 
hormonal products simulates a miniature hypothalamic-pituitary-target hormone 
unit. Among many of the analogues of the hypotEhalamic hormones produced in 
the placenta, GnRH exerts important effects on th-e autocrine/paracrine hormonal 
regulation within the placenta.
1. Important roles of GnRH in the physiological regulation of pregnancy
GnRH was first demonstrated in the human placenta in 1975 (Gibbons et al., 
1975). Since then, the expression of both GnRH gene (Dong et al., 1993) and its
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
4receptor gene (Peng et al., 1994) in the placenta has been well established. The 
findings that the contents of bioactive GnRH (Gibbons et al., 1975) and/or the 
GnRH receptor (Carrie et al., 1989) in the human placenta vary with gestational 
age suggested the important roles fo r GnRH during pregnancy. Further studies 
demonstrated that the placental GnRH is involved in the physiological regulation 
of production of hCG (Butzow et al., 1982), steroids and prostaglandins (Siler- 
Khodr et al., 1986). The placental GnRH also exhibits effect on interacting 
systems, such as CRH, and may be involved in the physiological regulation of 
pregnancy. Using in situ RT-PCR and immunocytochemistry, GnRH and GnRH 
receptor gene expression have been co-localized both in the cytotrophoblast and 
syncytiotrophoblast in first and third trimester placenta (Wolfahrt et al., 1998), 
further indicating autocrine/paracrine regulation by GnRH in the human placenta.
1.1. Placental GnRH regulates hCG release during the course o f human 
pregnancy
Physiological evidence has shown that maternal serum hCG levels vary in 
accordance with changes in the serum level of bioactive GnRH. The placental 
GnRH has also been demonstrated to actively stimulate the release of hCG from 
cultured trophoblasts (Khodr et al., 1978; Siler-Khodr et al., 1981; Butzow et al., 
1982; Petraglia et al., 1987). The effect of GnRH on hCG production varies with 
gestational age and can be blocked by GnRH antagonist. Further evidence 
showed that placental GnRH mediated in vitro opioids regulation of hCG release 
from term trophoblast tissue (Cemerikic et al., 1994). On the other hand, the
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
5changes of placental GnRH receptor mRNA expression paralleled the time 
course of hCG secretion during pregnancy, suggesting that the 
paracrine/autocrine regulation of hCG secretion by placental GnRH may be 
mediated by a decline in GnRH receptor gene expression from the first trimester 
to term placenta (Lin et al., 1995).
1.2. Placental GnRH affects the placental steroidogenesis competence within 
different gestational ages
Siler-Khodr et al. (1983) showed that GnRH analogs could affect placental 
hormone production and the outcome of pregnancy. Further, GnRH modulated 
the placental production of progesterone and estradiol in human placental cells of 
different gestational ages (Siler-Khodr et al., 1986; Brnachaud et al., 1983; 
Ringler et al., 1989). Since estrogen is responsible for the developmental 
regulation of placental 11 p-HSD/corticosteroid metabolism and activation of the 
fetal HPAA, it is most likely that GnRH is involved in maturation of the fetus via 
estrogen. However, recent studies in the placental JEG-3 choriocarcinoma cells, 
which more closely resemble term placenta, showed that GnRH does not affect 
steroidogenesis (Bauer et al., 1998). Thus, depending on physiological 
circumstances, GnRH affects steroid hormone synthesis in pre-term placenta, 
but might have no effect on near term placenta.
1.3. GnRH modulates prostaglandin release during gestation
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
6The production of human placental prostaglandin varies during gestation and 
its release in vitro is affected by GnRH, which related to the gestational age of 
placenta (Haning et al., 1982). Siler-Khodr et al. (1986) further confirmed these 
results, showing the dependence of first trimester placental prostaglandin 
production on endogenous GnRH. Since prostaglandins play an important role 
during pregnancy and labor, GnRH may be an important factor in the normal 
physiology of pregnancy.
1.4. In vivo evidence o f GnRH effects on placental tissue
In vivo studies on primate animal models and humans also support the notion 
that GnRH plays an important role in the physiology of pregnancy. For example, 
addition of GnRH antagonists to pregnant baboons in early pregnancy reduced 
the production of hCG and progesterone (Das et al., 1985). By measuring 
maternal circulating GnRH levels during pregnancy, Siler-Khodr et al. (1984) 
have found the women with abnormally low levels of circulating GnRH underwent 
premature labor or premature delivery.
1.5. The role o f GnRH in preimplantation embryonic development
Recent studies (Raga et al., 1999) on pre-implantation murine embryos at 
various developmental stages showed that GnRH agonist increased, whereas 
GnRH antagonist decreased, preimplantation embryonic development. Further, 
GnRH antagonist was able to completely block embryo development and this 
effect was reversed by increasing concentrations of the agonist. This indicated
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
7that GnRH might have an important role in preimplantation embryonic 
development as well.
2. Expression of the GnRH and GnRH receptor genes in the placenta
The human cDNA for GnRH was first cloned by Seeburg and Adelman in 
1984 (Seeburg et al., 1984). It is a single-copy gene that located on chromosome 
8, consisting of four exons and three introns (Fig. 1A). The GnRH gene 
transcribes an approximate 600 bp pro-GnRH mRNA, which encodes a precursor 
protein for the GnRH decapeptide. The GnRH precursor protein is well 
conserved across species in the region of the signal peptide and the decapeptide 
GnRH but diverges in the sequences encoding GAP (GnRH-associated peptide). 
In addition to the hypothalamus where the GnRH gene primarily expressed, 
increasing evidence has demonstrated the expression of GnRH gene in non- 
hypothalamic tissues, particularly in reproductive tissues. The non-hypothalamus 
expression of GnRH gene was further supported by the identification of an 
upstream GnRH promoter especially used in reproductive tissues, while the 
downstream promoter is mainly utilized by hypothalamic neurons (Fig. 1B) (Dong 
et al., 1993).
2.1. The existence o f bioactive and/or immunoreactive GnRH-like activity in the 
placenta
The presence of GnRH-like peptide was first reported in the human placenta 
in 1975 (Gibbons et al., 1975). Using carboxylmethyl-cellulose ion-exchange
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Fig. 1. The GnRH gene. A: The GnRH gene is coded for by four exons and three 
introns. Exon 1 encodes the 5’-untranslated region (5’UT) and exon 2 the signal 
peptide (Sig), the decapeptide GnRH, and GnRH-associated peptide (GAP). 
Exon 3 also codes for GAP, and exon 4 codes for the carboxyl region of GAP 
and the 3’-untranslated region (3’UT). B: Two transcriptional start sites of the 
human GnRH gene.
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9chromatography, Gibbons’ group demonstrated that human chorionic membrane 
and placental tissue contain GnRH-like substances. Homogenates prepared from 
fresh human term placenta caused release of luteinizing hormone when 
bioassayed in rats (Gibbons et al., 1975). Further, immunoreactive GnRH-like 
peptide was found in the human placenta by using radioimmunoassay and 
immunofluorescence microscopy (Siler-Khodr et al., 1978). Khodr et al. (1980) 
subsequently demonstrated that GnRH is synthesized by the placenta and can 
stimulate LH/hCG in vitro and in vivo. Moreover, GnRH antagonists prevent the 
GnRH-induced increase in hCG release as well as decrease basal hCG 
production in the human placenta (Siler-Khodr et al., 1983). In addition to the 
human placenta, the placentas of other animals were also found to contain 
GnRH-like peptide. Using GnRH radioimmunoassay, Nowark et al. (1984) 
demonstrated the presence of immunological GnRH-like activity in rabbit 
placenta collected in day 18 of gestation. The presence of bioactive and higher 
molecular forms of GnRH in the rat placenta was also reported (Sarkar, 1986). 
Thus, bioactive and/or immunoreactive GnRH-like peptide exists in the placenta.
Within the placenta, the presence of immunoreactive GnRH has been 
localized in the cytotrophoblast, villus stroma, and syncytiotrophoblast. Using 
immunofluorescent localization, Khodr et al. (1978) demonstrated that the GnRH 
activity could be localized predominantly in the cytotrophoblast of the 10-12 week 
human placenta. GnRH has also been found in the syncytiotrophoblast in very 
early gestation (Seppala et al., 1980). Immunocytochemical studies further 
confirmed that in placental villi at term, immunoreactive inhibin a and p A
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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subunits and GnRH had a distribution that was superimposable in several areas. 
Both the outer layer and the inner trophoblasts contained immunoreactive 
hormonal products (Petraglia et al., 1992). These findings provide an anatomical 
basis for a paracrine/autocrine modulation of GnRH in placental 
hormonogenesis.
The GnRH not only presents in the placenta, its level varies in accordance 
with different gestation periods as well. Radioimmunoassay studies in the human 
placenta indicated that the concentration of GnRH varies according to the 
duration of pregnancy but not the sex of the fetus. The human placenta of 15-40 
weeks gestation contains large amounts of GnRH-like activity with the highest 
concentration in early gestation (Siler-Khodr et al., 1978). The total 
immunoreactive GnRH content in the placenta, as measured by 
radioimmunoassay, progressively increases during the first 24 weeks of gestation 
and remains relatively constant in the third trimester. Using a quantitative 
immunohistochemical method, Miyake et al. (1982) detected the most intense 
staining for GnRH in the placenta during the 8th week of gestation with low 
staining during the remaining gestation period. The variable content of GnRH in 
the placenta has also been demonstrated in the rat (Sarkar, 1986). These data 
support the important role of placental GnRH during gestation.
2.2. Expression o f GnRH gene in the placenta
Immunocytochemical studies have demonstrated the presence of the GnRH 
peptide, but do not address whether the GnRH is maternal, fetal, or placental in
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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origin. To confirm the local production of the placental GnRH, many studies have 
been conducted to demonstrate the GnRH gene expression in the placenta. In 
1984, Seeburg and Adelman first reported the cloned genomic and cDNA 
sequences encoding the precursor form of GnRH in the human placenta. These 
DNA sequences code for a protein of 92 amino acids in which the LHRH 
decapeptide is preceded by a signal peptide of 23 amino acids and followed by a 
Gly-Lys-Arg sequence, as expected for enzymatic cleavage of the decapeptide 
from its precursor and amidation of the carboxy-terminal of LHRH (Seeburg et 
al., 1984). Furthermore, using an avidin-biotin-Cy.5 detection system in 
conjunction with laser scanning confocal microscopy, the presence of pro-GnRH 
was shown to be present in both cytotrophoblasts and syncytiotrophoblasts of 
placental villi. Southern blot and DNA sequence analysis showed that the 
hybridized transcript is identical to the hypothalamic GnRH. Immunocytochemical 
staining using an antiserum to amino acids 6-16 of pro-GnRH demonstrated the 
presence of translated pro-GnRH in both the cytotrophoblast and 
syncytiotrophoblast epithelia (Duello eta!., 1993).
Regarding the gestational-related changes of the placental GnRH mRNA 
content, Kelly et al. (1991) using solution hybridization/ribonuclease protection 
assay demonstrated that the levels of GnRH mRNA remain constant throughout 
gestation, in contrast to the observation that immunoreactive GnRH varies with 
the gestational age. This is supported by the findings that the changes of GnRH 
receptor mRNA parallel the time course of hCG secretion during pregnancy (Lin 
et al., 1995). It is most likely that the changes of GnRH receptor level, rather than
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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the GnRH level, Is responsible for the dynamic changes in GnRH mediated hCG 
secretion.
Because the expression of hGnRH gene in the human placenta primarily uses 
the upstream transcription start site, the upstream promoter may direct the 
tissue-specific expression of hGnRH in the human placenta. Dong et al. (1993) 
demonstrated that the upstream transcription start site (-579 bp from downstream 
transcription start site) lacks the TATA and CAAT elements often present in RNA 
polymerase II promoters, but contains the sequence GGTCTTGCT located 84 bp 
5' to the upstream transcriptional start site similar to other genes that lack 
TATA/CAAT boxes. Further, human and monkey are highly homologous in the 
upstream promoter region of GnRH gene with a similar gene expression pattern 
but different from those of rat and mouse (Dong et al., 1996), suggesting that the 
dual promoters of GnRH gene are conserved within primates. Subsequent 
studies also demonstrated that the mRNA transcribed from upstream promoter is 
capable o f directing translation into GnRH precursor in vitro, and identified the 
region between -1048 bp and -723 bp important for the upstream promoter 
activity in the human placenta (Dong et al., 1997). Thus, the upstream promoter 
of GnRH gene directs the tissue-specific expression of GnRH gene in the 
placenta.
2.3. Expression o f GnRH receptor gene in the placenta
GnRH stimulates the release of hCG from cultured placental cells and 
placental explants in a dose-dependent manner (Khodr et al., 1978; Butzow et
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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al., 1982). This stimulatory action of GnRH can be blocked by GnRH antagonists 
(Currie et al., 1992; Bamea et al., 1991). These findings indicate that the role of 
GnRH in the placenta is receptor mediated. Further studies demonstrated the 
presence of highly specific, moderate affinity GnRH binding sites in the human 
placental membrane (Currie et al., 1989; Belisle et al., 1984; Iwashita et al., 
1986; Bramley et al., 1992). However, placental GnRH binding sites differ from 
those of pituitary GnRH receptors. First, placental GnRH binding sites do not 
distinguish between GnRH and agonist analogues with super-activity in the 
pituitary. Hence, rat pituitary and human placental binding sites have similar 
potencies for GnRH, but different potencies for GnRH agonists. Second, pituitary 
GnRH receptors do not bind non-mammalian isoforms of GnRH, whereas human 
placental GnRH binding sites bind chGnRH II, sGnRH. Third, a number of GnRH 
antagonists with high affinity for pituitary GnRH receptors bind poorly to human 
placental binding sites (Bramley et al., 1994).
Using in situ hybridization, Lin et al. (1995) demonstrated that GnRH receptor 
mRNA is expressed in both cytotrophoblasts and syncytiotrophoblasts and 
exhibits changes paralleling the time course of hCG secretion during pregnancy, 
further supporting autocrine/paracrine modes of action for GnRH in regulating 
hCG secretion. Thus, it is most likely that placental GnRH is a primary 
autocrine/paracrine regulator of hCG secretion, and that the functionality of the 
GnRH-hCG system is controlled by the changes in GnRH receptor gene 
expression during the course of human pregnancy.
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3. Regulation of the GnRH secretion in the placenta
A plenty of data indicate that the placenta produces a variety of pituitary and 
hypothalamic-like hormones and peptide, growth factors and their receptors, as 
well as the inhibin family of gonadal peptides. Further evidence reveals that the 
hormonal regulation within the placenta may be paracrine, autocrine, or 
endocrine, simulating a miniature hypothalamic-pituitary-target hormone unit, in 
which GnRH has an important central role.
3 .1. Steroid hormone regulation o f placental GnRH secretion
Steroid hormones play important roles in the physiology of pregnancy. For 
example, estrogen and progesterone are involved in initiating and maintaining 
pregnancy, while glucocorticoids affect parturition. Increasing evidence has 
indicated that steroid hormones can modulate GnRH release in the placenta. 
Studies conducted in placental cultures showed that both estriol and estradiol 
increased, while progesterone decreased, the immunoreactive GnRH (irGnRH) 
release induced by 8-bromo-cAMP. The stimulatory effect of estriol or estradiol 
was reversed by the concomitant addition of progesterone. Estriol increased, 
while progesterone decreased, the secretagogue effect of activin on irGnRH 
release from cultured placental cells. The action of estriol was counteracted by 
both tamoxifen, an estrogen antagonist, and progesterone. The inhibitory effect 
of progesterone was completely reversed by RU486, a specific progesterone 
receptor antagonist. Thus, steroid hormones and opiate receptor agonists 
influence irGnRH release from human cultured cells, suggesting that local
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interaction between steroids and peptides modulates irGnRH release from 
human placenta (Petraglia et al. 1990). These observations are consistent with 
previous studies of estrogen’s increasing and progesterone’s decreasing basal 
and GnRH-stimulated hCG release and hCG mRNA levels (Ringler et al., 1989; 
Wilson et al., 1984; Maruo et al., 1986). In human placenta, the presence of 
estrogen receptor and progesterone receptor has been demonstrated (Younges 
et al., 1981; Chibbar et al., 1995; Shanker et al., 1997 and 1998; Rossmanith et 
al., 1997), further supporting the concept that steroid hormones modulate 
placental GnRH secretion.
3.2. Activin and inhibin regulation o f placental GnRH secretion
Since activin and inhibin, which are gonadal glycoproteins but possess 
opposing activities, are also produced in the placenta (Meunier et al., 1988; 
Petraglia et al., 1989), they may modulate placental hCG production by 
regulating GnRH activity as well. The addition of inhibin antiserum to placental 
cell cultures increased GnRH release and a parallel rise in hCG secretion. This 
effect was reduced by addition of a GnRH antagonist, suggesting the interaction 
of inhibin and GnRH on hCG secretion. Furthermore, addition of purified inhibin 
had no effect on hCG or GnRH production but reversed GnRH induced hCG 
secretion from cultured placental cells. In contrast, activin increased the GnRH 
induced secretion of hCG in cultured trophoblast cells, an effect that was reduced 
by the addition of inhibin (Petraglia et al., 1989). These results suggest that
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inhibin and activin may play a role in regulating the release of GnRH, hC G , and 
progesterone from placenta.
3.3. Regulation o f placental GnRH secretion by other biomolecules
Evidence has shown that cell membrane depolarization stimulates the release 
of placental GnRH by promoting the influx of calcium into the cell as occurs  in the 
hypothalamus. Prostaglandins (PGE2 and PGF2) and epinephrine stimuUate the 
release of GnRH from placental cells, probably acting through cAMI P. The 
epinephrine-induced GnRH release can be reversed by propranololl (a |3- 
adrenergic receptor antagonist), suggesting the involvement of p-adrrenergic 
receptors in regulating placental GnRH release (Petraglia et al., 1987). Insulin 
and vasoactive intestinal peptide can also stimulate placental GnRH release in a 
dose-dependent manner (Petraglia et al., 1990), as can EGF (Barneai et al., 
1990).
4. Regulation of the GnRH gene expression in the placenta
Complex mechanisms have evolved to ensure proper spatial and teemporal 
expression of genes in differentiated tissues. In part, this control is achieved at 
the transcriptional level, so that regulatory regions containing multiple ciss-acting 
sequence elements control both the level of gene expression and its restrioction to 
appropriate cell types. Simply, tissue-specific gene expression is achieved 
through DNA binding of a transcription factor restricted to a particular c e ll type 
(Johnson et al., 1989; Mitchell et al., 1989). However, more commonly, tissue-
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specific expression is the result o f a unique combination o f sequence elements 
binding more broadly expressed proteins.
4.1. Cis-regulatory elements involved in GnRH promoter activity
To better understand the regulation of placental GnRH production, especially 
at the pre-translational level, the human placental choriocarcinoma cell line JEG- 
3 has been widely used as an in vitro placenta model to study the hGnRH 
promoter activity in the placenta (Radovick et al., 1990, 1991; Wierman et al., 
1992; Dong et al., 1993). Radovick and his colleague (1991) observed a 
stimulatory effect of estradiol on the hGnRH promoter activity in JEG-3 cells. The 
investigators demonstrated a 32 bp sequence between -534 and -521 bp 
mediated the stimulatory response to estrogen. In contrast, Wierman et al. (1992) 
observed no stimulatory by estradiol in similar constructs using the rat GnRH 
(rGnRH) promoter in JEG-3 cells. Estrogen consistently negatively regulated 
rGnRH promoter activity via an ER dependent mechanism. The sequences 
important for placental cell expression and estrogen regulation of rGnRH locate 
in the region from -73  to -16. Further, potential repressor sequences active in 
placental cells are present between -903 to +424. It is of interest that the 
sequences identified as the positive estrogen responsive element (ERE) in the 
hGnRH promoter are not conserved in the rat (Adelman et al., 1986; Bond et al., 
1989) or mouse (Mason et al., 1986) GnRH genes. Thus, the opposing effect of 
estrogen on GnRH may represent the species-specific difference between the 
human and rat GnRH genes (Dong et al., 1997). In addition, Dong et al. (1996)
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demonstrated that estrogen directly down-regulates the hGnRH upstream 
promoter activity in JEG-3 cells via estrogen receptor a  (ERa). The negative 
regulatory effect of estrogen on the GnRH upstream promoter has also been 
observed in the Chinese hamster ovary-derived CHO-K1 tumor cells (Chen et al., 
1999). Further studies showed that cortisol and its synthetic analogue, 
dexamethasone, can stimulate the hGnRH upstream promoter activity in 
transfected JEG-3 cells in a glucocorticoid receptor (GR)-dependent manner, 
suggesting that cortisol is physiologically involved in the regulation of GnRH gene 
expression in the human placenta (Chen et al., 1998). These data strongly 
suggest that steroid hormones are directly involved in the regulation of placental 
GnRH gene expression through specific cis-regulatory elements and their 
different effects on the GnRH gene expression might be dependent on the 
variations of species, tissues, receptor contents, and DNA sequences.
4.2. Trans-acting factors involved in GnRH promoter activity
Regarding the trans-acting proteins involved in the regulation of GnRH gene 
expression, the POU-homeodomain protein Oct-1 has been demonstrated to be 
an important transcriptional factor mediating GnRH gene expression. Oct-1 is 
known to be expressed in a variety of tissues and cell types (Sturm et al., 1987) 
including JEG-3 cells and GT1-7 cells, it is believed that Oct-1 participates in 
tissue-specific gene expression by interaction with either other transcription 
factors (Voss et al., 1991;Poellinger et al., 1992) or tissue-specific co-activators 
(Luo et al., 1992; Strubin et al., 1995). The role of Oct-1 in tissue-specific
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expression has been demonstrated in GT1-7 cells for rat GnRH and mouse 
GnRH (Clark et al., 1995; Eraly et al., 1998; Chandran et al., 1999) and in JEG-3 
cells for leukemia inhibitory factor receptor (LIFR) gene (Wang et al., 1998). 
Another POU-homeodomain protein SCIP/Oct-6/Tst-1 has also been reported to 
be able to regulate rat GnRH promoter activity in GT1-7 cells (Wierman et al.,
1997). Also, GATA factors have been shown to be essential for activity of the 
neuron-specific enhancer of rat GnRH gene (Lawson et al., 1996). In addition, 
other studies demonstrate that Fos and Jun transcription factors mediate down- 
regulation of both human and rodent GnRH promoter activity in neuronal cell 
lines (Zhen et al., 1997;Bruder et al., 1996). However, the transcription factors 
involved in GnRH gene expression in the placenta are still unknown.
5. Interactions of placental GnRH as well as other biomolecules in the 
placenta
In summary (Fig. 2), GnRH stimulates the release of hCG, which in turn 
stimulates the release of steroid hormones. Estrogen negatively, and 
progesterone positively, exert feedbacks to the GnRH production. The hCG also 
negatively feedback to the GnRH production. Furthermore, activin positively, and 
inhibin negatively, regulate the release of the placental GnRH. Therefore, 
placental GnRH interacts with hCG, steroid hormones, as well as other 
biomolecules in the placenta to regulate placental steroidogenesis, indicating an 
important physiological role of placental GnRH in the maintenance of the function 
of placental-ovarian axis and pregnancy.
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Fig. 2. Paracrine/autocrine regulation of GnRH in the placenta.
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SPECIFIC AIMS OF THE STUDY
Specific Aim 1: Characterize the hGnRH upstream promoter cis-regulatory 
elements and trans-acting factors that are responsible for tissue-specific 
expression of the GnRH gene in the human placental JEG-3 cells.
1.1. Analyze the hGnRH upstream promoter cis-regulatory elements for their 
contributions to the tissue-specific expression of hGnRH gene in JEG-3 cells.
1.2. Identify trans-acting factors that interact with the hGnRH upstream promoter 
elements for tissue-specific expression in JEG-3 cells.
Specific Aim 2: Investigate the roles of estrogen, estrogen receptor a and p 
in the regulation of the hGnRH upstream promoter activity in JEG-3 cells.
2.1. Determine the expression of human estrogen receptor a (hERa) and p 
(hERp) genes in JEG-3 cells.
2.2. Study the roles of estradiol, hERa and hERp in the regulation of the hGnRH 
upstream promoter activity in JEG-3 cells.
2.3. Compare hERa and hERp mediated effects of estrone, estradiol, and estriol 
on the upstream promoter activity of the hGnRH gene in JEG-3 cells.
2.4. Investigate the interactive effects of hERa and hERp on the hGnRH 
upstream promoter activity in JEG-3 cells.
2.5. Analyze the negative and positive estrogen responsive elements in the 
hGnRH upstream promoter region.
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Specific Aim 3: investigate the roles of progesterone, progesterone 
receptor A and B forms in the regulation of the hGnRH upstream promoter 
activity in JEG-3 cells.
3.1. Determine the expression of human progesterone receptor A (hPR-A) and B 
(hPR-B) genes in JEG-3 cells.
3.2. Study the roles of progesterone, hPR-A and hPR-B in the regulation of the 
hGnRH upstream promoter activity in JEG-3 cells.
3.3. Examine the effects of coactivators, SRC-1 and CBP, on hPR-A and hPR-B 
mediated progesterone regulation of the hGnRH upstream promoter activity in 
JEG-3 cells.
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EXPERIMENTAL DESIGN
Specific Aim 1: Characterize the hGnRH upstream promoter cis-regulatory 
elements and trans-acting factors that are responsible for tissue-specific 
expression of the GnRH gene in the human placental JEG-3 cells.
Rationale: The human GnRH gene consists of two transcription start sites: the 
upstream transcription start site is primarily utilized in human reproductive 
tissues, while the downstream transcription start site is mainly used in the 
hypothalamus (Dong et al., 1993). Further studies demonstrated a 325-bp region 
(-1048 to -723) mediates the upstream promoter activity of the hGnRH gene in 
the human placental JEG-3 cells (Dong et al., 1997). DNase I footprinting 
analysis of the upstream promoter region revealed four specific footprinted 
elements (FP1, -876 to -851; FP2, -919 to -896; FP3, -960 to -940; FP4, -987 to 
-968) (Fig. 3) that are capable of binding to the nuclear extract from the human 
placental JEG-3 cells but not from the hypothalamic neuronal GT1-7 cells. The 
interaction of nuclear proteins from JEG-3 cells with these four elements was 
further confirmed by gel mobility shift assay (Dong et al., 1997). These results 
suggest that the four footprinted elements may be involved in the tissue-specific 
expression of the hGnRH gene in the placenta. This is supported by the 
observation that by constructing transgenic mice with various fragments of the 
hGnRH gene 5’-flanking region, a fragment between -1131 and -484  of the 
hGnRH gene is essential for tissue-specific expression of the hGnRH gene
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- 1 6 9  9 AAGCTTGCATGCCTGCAGGTCGACTCTAGAGAATGCTGAGTAATACAATATTGCTGTGTT 
- 1 8  3 9 CATCTTAATAATTTCAAAACATTCTTCAAAAATTTAATCCCAACTGTTAGAAATAACCTA  
- 1 7  7 9 CAAGAAATCCAGTGAGGCCTACCTACCCAGAGATAAGTGATT<2a CCTGACAATATGCATC 
- 1 7 1 9  ACAAGTCTTAACTCTCATTTCATTAGTCCTATCCAGAGACCACATTTTCTACTTAAGCAA 
—1 6 5  9 TACTTAGAGGCACAT CTCT CAGCAAACACAAACC AAT T  GGACAATT TAAACTAGCA CT AT 
- 1 5  9 9 TCAACCATAATGAACTCTGGTTGAAAAACAGTCTGTCCCTACTTGCATAXTGTAGTGAGA 
—1 5  3  9 TGAGATTCC&CTCTTCArGTCAGAATGGCACTTACATGAGTCAAAGTGTCTAAATGAaAT 
- 1 4  7  9 AATTTAAATGGAACAAAGTCAAATACTTACATTTTATTTTTAAATTCTCCTCTATTTGCC  
- 1 4 1 9  AGTTATACTTTAAAOTGTACTCCCTT CT CTATCCTAT CAT GAGGACT GGACAGCCT CCAC 
- 1 3  5 9 AGAGATGGCTGGACAAAGCAAGGGAATTTACTTAGGTAAGACACCATTTCTCTTTACTCT
- 1 2  9 9 g a a a t c c c t g c a a a t g t a g t t a t t c c a g a g g a g a c t g t g c a a t g a c t g a t g g g t t t a g c a
—1 2 3 9  TCCTACATGAGGGGAAATTGCCATTCCCAGCTGTAAAATGAACAAATATCCAGTTATTTT 
- 1 1 7  9 TTTTAGCCATCTTACAGCTTAGCTAATATAACAGGATTTACAGCCAATTATACATGAAAG  
- 1 1 1 9  TTTAATTCTGTGTCAGATAAAGCATATCTTTGATGCAGAAATAGAGGCAGCATTAGGCCT
H in d  III
- 1 0 5 9  TACCTGGTTAAAAGCTTTTTGCTTTCTAT TCATTCGTTCATTCATTCATTCATTCAAACC
-1048
- 9  9 9 TATACTTACCGAATGCTCACTAAATGCCGGGGGTTTATTAAGAGAGATTTAAATAAGATG
-987 Footprint/Gal Shift -968 -960 FootprlntfGel &hi»t -940
- 9 3 9  g g a t c t t t g &c t a t t a c a g g t t t c a g c c t a g g g g t a a a t t r g g g o a a g a c a a c c a t g t a t
-919 Foo(print/G«l Shift -896 
—8 7 9  TCAAATAAATGTAATAAGAGTAATGGTTGTGTGTGTATTTTACATGCTTGTCCTGTGTAA 
-876 Footprinti'Gel Shift -849
- 8 1 9  ATAACACGTCCACGGTTGCACCTCTGGGGTGGAACATCTATAAAATTTAGATAATGATAC
A fl II
- 7  5 9 CCACTTTGCATGGCTATTGT AATGAGTGCTTAAGTCAAT AAGCATCTACTGAAATGAGTT
-723
- 6 9 9  g a t c t g t t g a t g t a a g t c t g c t c a a t a g g t c t t g c t c t c a g a a t a t g t t t c t t g c c t t t t  
- 6 3 9  t g a t g c t t t a g a a g g c t t t c a a g g t a a g t c a a g c a g g g a a c c t g g t g g g g t a g a t g a g g g  
- 5 7  9 I a t t t t c a a a c a c a c a a c t g t c t g a it t a g g a t c c t a c a t g g a c t t g g t a t a t a g t g t c a
- 5 1 9  G TTACTT GTAAAT CAGATTT T TAAAATT GGAAGCAACT CTGT GAT CAT CTAGT C CAT CTA 
- 4  5  9 GTCTACACCCTTCCTTTTACAAATGAAGAATCCAAGAGCCAGAAGCTCCCAGACATCCTG
Fig. 3. DNA sequence of the hGnRH 5’-fIanking region. The numbers are 
relative to the downstream transcription start site of the hGnRH gene. The 
upstream transcription start site is shown as a bent arrow at -579. The DNAse 
footprinting regions are underlined.
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(Radovick et al., 1990). The present study is designed to analyze in detail the 
contributions of the four footprinted elements, individually or in combination, to 
the tissue-specific hGnRH upstream promoter activity in the human placental 
JEG-3 cells. To achieve this goal, PCR and restriction enzyme digestion will be 
applied to generate individual or combined four element(s). These upstream 
promoter elements are subsequently cloned into TK/luciferase reporter vector for 
transient transfection studies in JEG-3 cells.
In addition, detailed sequence analysis revealed that the four footprinted 
elements are short AT-rich regions with octamer motif (consensus sequence 
ATGCAAAT) that are possible bound by the POU-homeodomain transcription 
factors. The importance of the POU-homeodomain protein Oct-1 in the regulation 
of gene expression has been demonstrated in the neuronal GT1-7 cells for rat 
and mouse GnRH (Eraly et al., 1998; Chandran et al., 1999), and in the placental 
JEG-3 cells for leukemia inhibitory factor receptor (LIFR) gene (Wang et al., 
1998). It is believed that Oct-1 is involved in the tissue-specific gene expression 
by interacting with other transcription factors (Voss et al., 1991; Poellinger et al., 
1992) or tissue-specific coactivators (Luo et al., 1992; Strubin et al., 1995). 
Thus, Oct-1 may be involved in the tissue-specific expression of the hGnRH in 
the placenta. In the present study, gel mobility shift and super-shift assays will 
be conducted by using nuclear extract from JEG-3 cells and specific antibody 
against Oct-1 protein to determine whether Oct-1 protein is involved in the DNA- 
protein interaction of the footprinted upstream promoter elements.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
26
Experimental design:
1.1. Analyze the hGnRH upstream promoter cis-regulatory elements for their 
contributions to the tissue-specific expression o f hGnRH gene in JEG-3 cells.
To determine the contributions of the individual or combined footprinted 
elements for the hGnRH upstream promoter activity in the placenta, the human 
placental choriocarcinoma cell line JEG-3 was utilized as in vitro human placental 
model. Functional transient transfections were performed in JEG-3 cells using 
calcium phosphate coprecipitation assay with co-transfected pCMV p- 
galactosidase plasmid as control for transfection efficiency. Using PCR with 
specific primers, the individual or combined DNA sequences of the four 
footprinted elements were generated. Each of the amplified DNA fragments was 
inserted into a herpes simplex thymidine kinase (TK) minimal promoter/luciferase 
reporter vector, pT109luc, to produce hGnRH upstream promoter elements)/TK- 
luciferase constructs (TKU432, TKU43, TKU4, TKU321, TKU21, TKU1, TKU421, 
and TKU431). A 272-bp fragment (-994 to -723) containing the four footprinted 
elements derived from the full-length 5’-flanking region of the hGnRH gene was 
cloned into the pT109luc to produce TKU (Fig. 4).
The constructs o f TK, TKU, and hU that contains the full length 5-flanking 
region of the hGnRH upstream promoter were transfected into the human 
placental JEG-3 cells, neuron GT1-7 cells, and non reproductive tissue human 
kidney 293 cells, respectively, to examine the four elements in directing tissue- 
specific hGnRH upstream promoter activity. Subsequently, the constructs 
containing individual or combined element(s) were transfected into JEG-3 cells to
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(-► D1 
-960 -940
r*-B1
-876 -849 -729
r>C 1
-919 -896-987 -968
FP3FP4 FP1FP2
-1059
Xba I Hind III Affll
FP4 FP3 LUCFP2 FP1
-1899 -1048 -723 -579 -202
hU
FP2FP4 FP3 FP1 TK LUC
-994 -723
TKU
TK LUC TK
Fig. 4. Schematic structures of plasmid constructs. The four footprinted elements 
are represented as FP1-FP4. A1, A2, B1, C1, C2, D1, D2, and E2 are 
oligonucleotides used for PCR to generate individual or combined four 
footprinted element(s)/thymidine kinase (TK)-luciferase constructs (TKU1, 
TKU21, TKU321, TKU432, TKU43, TKU4). The hU luciferase construct contains 
the 5’ full-length hGnRH upstream promoter region inserted into promoter-less 
pxp2-luciferase vector. The upstream transcription start site is shown as bent 
arrow. TKU was made by inserting the fragment (-994 to —723) containing the 
four footprinted elements into pT109luc vector. TK is the pT109luc itself.
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determine the contributions of different combinations of the four elements in 
mediating the hGnRH upstream promoter activity in JEG-3 cells. Also, a set of 5’ 
end deletion in the hGnRH upstream promoter/luciferase constructs that retain 
the original hGnRH upstream promoter was transfected into JEG-3 cells to 
further confirm the roles of the four elements in the tissue-specific upstream 
promoter activity in JEG-3 cells. In addition, mutational studies on the element(s) 
that may direct major upstream promoter activity were conducted to support the 
functional roles of these cis-regulatory elements in the hGnRH upstream 
promoter activity.
1.2. Identify trans-acting factors that interact with hGnRH upstream promoter 
elements for the tissue-specific expression in JEG-3 cells.
Sequence analysis of the four footprinted elements indicated the presence of 
possible binding sites for the POU-homeodomain protein Oct-1. EMSA and 
supershift assays were, therefore, performed with nuclear extract from JEG-3 
cells and specific antibody against Oct-1 to determine whether Oct-1 protein 
involved in the DNA-protein interaction of the four footprinted elements. The 
probes were prepared by annealing wild-type oligonucleotides of the four 
elements and labeled with [y-32P]ATP. Also, western blot assay was conducted 
with specific antibody against Oct-1 to determine the presence of Oct-1 protein in 
our JEG-3 cells.
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Specific Aim 2: Investigate the roles of estrogen, estrogen receptor a and {3 
in the regulation of the hGnRH upstream promoter activity ira JEG-3 cells. 
Rationale: Estrogen is one of the major hormones produced in *he  placenta and 
its plasma level varies greatly with gestation. The placenta also produces GnRH 
that plays an important role in reproductive tissues as well as pregnancy. It is 
known that estrogen through estrogen receptor affects the G nRH production in 
the placenta (Petraglia et al. 1990). Further studies demonstrated the direct 
effect of estrogen on the hGnRH promoter activity in the placemta (Radovick et 
al., 1991; Dong et al., 1996). Recently, a negative and a positive estrogen 
responsive element have been identified in the hGnRH ups=tream promoter 
region (Chen et al., 1999 and 2000). Thus, it is of interesting to* understand the 
mechanisms behind the estrogen actions on the upstream promoter.
The physiological response to steroid hormones is generally mediated by 
specific intracellular receptors. It is known that steroid hormones receptors exist 
as multi-forms with distinctive tissue distributions and functions. The human 
estrogen receptor has two major subtypes, estrogen receptor c l (hERa) and p 
(hERp) (Fig. 5. A) (Kuiper et al., 1997; Paech et al., 1997). E R p has the DNA 
binding domain that is almost identical to the homologous ER*x, implying that 
both ERa and ERp might share the same DNA response element! They can also 
form heterodimer complex, suggesting their possible cross-talkingj (Sumito et al.,
1998). However, ERa and ERp have different activation function region and 
ligand binding domain that might result in the distinctive ttransactivational 
mechanisms. Also, ERp has been shown to distribute in tissues differently as
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Fig. 5. Schematic representation of human estrogen receptor (hER) and 
progesterone receptor (hPR). A/B: activation function-1 (AF-1) domain; C: DNA 
binding domain; D: hinge domain; E/F: ligand binding and activation function-2 
(AF-2) domain. A. hERa and hERp. The well-conserved domains are DNA 
binding domain (96%) and ligand binding domain (60%). B. hPR-A and hPR-B. 
hPR-A lacks 164 amino acids at the N-terminus that are present in the full-length 
966-amino acid hPR-B.
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compared to ERa (Paech et al., 1997). Some tissues contain exclusively ERa 
(such as kidney) or predominant ERa (i.e. uterus, pituitary, epididymis), while 
other tissues show equal or greater levels of ERp RNA (i.e. ovary, prostate), 
implying distinctive physiological roles for ERp. In the human placenta, the 
presence of estrogen receptor has been demonstrated (Younges et., 1981; 
Chibbar et al., 1995). Further studies showed both ERa and ERp are present in 
the placenta (Brandenberger et al., 1997; Moore et al., 1998). However, the 
human placental JEG-3 cells have been reported to be deficient in ER 
(Chatterjee et al., 1989). As an in vitro human placenta model, JEG-3 cells have 
been utilized in studying estrogen regulation of GnRH gene expression in the 
placenta by exogenous expression of ER in the cells (Wierman et al., 1992; Dong 
et al., 1996). In the present studies, the presence of hERa and hERp in our JEG- 
3 cells will be first examined. Further, hERa and hERp expression plasmids will 
be transfected into JEG-3 cells to investigate the receptor-mediated estrogen 
regulation of the hGnRH upstream promoter activity.
Experimental design:
2.1. Determine the expression o f human estrogen receptor a  (hERa) and (3 
(hER/3) genes in JEG-3 cells.
To determine whether hERa and/or hERp are expressed in our JEG-3 cells, 
RT-PCR was conducted on cytoplasmic RNA from JEG-3 cells by using specific 
primers for hERa and hERp. MCF-7 cells, which express hERa and hERp 
proteins (Dotzlaw et al., 1997), were used as positive control. If the expressions
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were low or no expression, hERa and hERp expression vectors would be 
transfected into JEG-3 cells to mediate the effect of estrogen.
2.2. Study the roles o f estradiol, hERa and hERfi in the regulation o f the hGnRH 
upstream promoter activity in JEG-3 cells.
To investigate the effect of estradiol on the hGnRH upstream promoter 
activity in JEG-3 cells, transient transfections were performed in JEG-3 cells with 
the hGnRH upstream promoter/luciferase construct (hU) and pCMV p- 
galactosidase plasmid, with or without hERa or hERp expression vectors. The 
cells were then treated with 10 nM of estradiol with or without 1 p.M of IC1164,384 
for 20 h. The ICI164,384, a potent antiestrogen for both hERa and hERp, was 
used to determine whether the effect of estrogen was ER-mediated. The cell 
lysates were assayed for luciferase activity and p-galactosidase activity as a 
control for transfection efficiency. To confirm the actions of hERa and hERp in 
mediating estrogen effect on the hGnRH upstream promoter, various amounts of 
hERa or hERp (from 0.25 pg to 4 jig) were co-transfected with hU into JEG-3 
cells and treated with 10 nM of estradiol to study the dose effect of exogenous 
ER expression on the promoter activity.
To determine whether the estradiol effect was dose-dependent, JEG-3 cells 
were transfected with hU plasmid and hERa or hERp expression vectors, and 
treated with various concentrations of estradiol (from 0.01 nM to 100 nM) for 20 
h. The lysates were assayed for luciferase activities. The doses of estradiol 
applied were within its physiological range during gestation. The pCMV p-
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galactosidase plasmid was also co-transfected into JEG-3 cells with test 
construct(s) to correct for variations in transfection efficiency.
2.3. Compare hERa and hER/3 mediated effects o f estrone, estradiol, and estriol 
on the upstream promoter activity o f the hGnRH gene in JEG-3 cells.
To determine the effects of different estrogen isoforms on the hGnRH 
upstream promoter activity in the placenta, JEG-3 cells were transfected with the 
hGnRH upstream promoter/luciferase plasmid (hU) and hERa or hERp 
expression vectors. The cells were then treated with 10 nM of estrone, estradiol, 
or estriol, respectively, and harvested after 20 h incubation. The cell lysates were 
assayed for luciferase activities. The pCMV p-galactosidase plasmid was also 
co-transfected into JEG-3 cells with test construct(s) to correct for variations in 
transfection efficiency.
2.4. Investigate the interactive effects o f hERa and hER/3 on the hGnRH 
upstream promoter activity in JEG-3 cells.
The hERa and hERp have distinctive transactivational functions and can form 
heterodimer to cross-talk to each other. To see if hERa and hERp could 
modulate each other in mediating the estrogen effect on the hGnRH upstream 
promoter, various amounts of hERa and hERp expression vectors were 
transfected into JEG-3 cells with the hGnRH upstream promoter/luciferase 
construct (hU). In one experiment, 1 pg of hERa was introduced with various 
amounts of hERp (from 0.25 pg to 4 pg). In another experiment, 1 pg of hERp
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was transfected with various amounts of hERa (from 0.25 pg to 4 pg). Thus, the 
ratio of transfected hERa and hERp (hERa/hERp or hERp/hERa) was kept at 
4:1, 2:1, 1:1, 1:2, and 1:4. The cells were then treated with 10 nM of estradiol for 
20 h, and lysates were assayed for luciferase activities. Transfection efficiency 
was corrected by co-transfection of pCMV p-galactosidase plasmid with test 
construct(s). In addition, RT-PCR was conducted on the cytoplasmic RNAs 
prepared from hERa and/or hERp transfected JEG-3 cells with specific primers 
for hERa and hERp to confirm the transfection of hERa and hERp in JEG-3 cells.
2.5. Analyze the negative and positive estrogen responsive elements in the 
hGnRH upstream promoter region.
Previous studies in our laboratory have identified a negative and a positive 
estrogen responsive element in the hGnRH upstream promoter. To further verify 
these findings, functional mutation studies were performed on these two 
elements. Using PCR with specific primers, the negative estrogen responsive 
element was replaced by two unrelated DNA sequences, while the positive 
element was replaced by one unrelated DNA sequence, and cloned into 
promoter-less luciferase reporter, pxp2-luc. These constructs were transfected 
into JEG-3 cells, respectively, with hERa or hERp and pCMV p-galactosidase 
plasmid as control for transfection efficiency. The cells were then treated with or 
without 10 nM of estradiol for 20 h and assayed for luciferase activities.
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Specific Aim 3: Investigate the roles of progesterone, progesterone 
receptor A and B forms in the regulation of the human GnRH upstream 
promoter activity in JEG-3 cells.
Rationale: It is well known that progesterone plays an important role in
pregnancy and involves in the regulation of hypothalamic-pituitary-gonad axis. 
This regulation has been shown to be mediated by progesterone receptor (PR) 
(Kim et al., 1985). It is further supported by in vitro study in GT1-7 cells that direct 
DNA binding of PR to nonconsensus elements in the proximal rat GnRH 
promoter inhibits rat GnRH gene expression (Kepa et al., 1996). In the human 
placenta, progesterone decreases the release of immunoreactive GnRH and this 
action is mediated by its receptor (Petraglia et al., 1990). Using ribonuclease 
protection assay, PR mRNA has been detected in the human placenta (Chibbar 
et al., 1995). Further, Shanker et al. (1997) using RT-PCR demonstrated the 
expression of PR mRNA in the first trimester human placenta. Subsequently, the 
presence of PR was reported at all stages of placental development (Rossmanith 
et al., 1997). In addition, human PR exists as two isoforms, hPR-A and hPR-B 
(Fig. 5B), that are produced from a single gene by alternative translation (Kastner 
et al., 1990). They have similar DNA and ligand binding affinities but different 
functions (Giangrande et al., 1997; Bethea et at., 1998). The hPR-B functions as 
a transcriptional activator in most contexts, whereas in most cells hPR-A does 
not activate transcription but functions as a strong trans-dominant repressor of 
hPR-B (Vegeto et al., 1993). Recently, the presence of only PR-A but not PR-B in 
the first trimester and term placenta has been reported (Shanker et al., 1998).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
36
Therefore, the different receptor isoforms of PR may have distinctive roles in 
mediating progesterone actions on the regulation o f the hGnRH gene expression.
Co-regulators, steroid receptor coactivator-1 (SRC-1) and CREB binding 
protein (CBP), have been reported to exert important roles in nuclear receptor 
mediated gene expression. It has been shown that SRC-1 and CBP, 
independently or synergistically, enhance PR dependent transcription in a variety 
o f cell lines (Onate et al., 1995; Lundblad et al., 1995; Smith et al., 1996). Since 
these coactivators have been demonstrated to be expressed ubiquitously (Misiti 
et al., 1998), SRC-1 and CBP may be also involved the hPR-A and hPR-B 
mediated regulation of the hGnRH gene expression in the placenta.
Experimental design:
3.1. Determine the expression o f human progesterone receptor A (hPR-A) and B 
(hPR-B) genes in JEG-3 cells.
RT-PCR was performed on the cytoplasmic RNAs from JEG-3 cells and 
MCF-7 cells with specific primers for PR. MCF-7 cells, which express both PR 
isoforms, as well as hPR-A and hPR-B expression vectors were used as positive 
control. Because hPR-A and hPR-B are produced by alternative translation, 
western blot assay with specific antibodies against hPR-A/B and hPR-B was 
performed on the proteins from JEG-3 cells to determine what kind of PR 
expressed in our JEG-3 cells, hPR-A or hPR-B, or both.
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3.2. Study the roles o f progesterone, human progesterone receptor A and B in 
the regulation o f the hGnRH upstream promoter activity in JEG-3 cells.
The stimulatory effect of progesterone on the hGnRH upstream promoter 
activity has been demonstrated previously in our laboratory. In the present study,
I focused on the difference between hPR-A and hPR-B in mediating the 
progesterone effect on the upstream promoter. Using calcium phosphate 
coprecipitation method, the hGnRH upstream promoter/luciferase plasmid (hU) 
was transfected into JEG-3 cells with hPR-A or hPR-B expression vectors. The 
cells were treated with 0.1 nM of progesterone for 20 h, and lysates were 
assayed for luciferase activity. Also, a progesterone antagonist (RU486) was 
used to block the receptor-mediated pathway to further confirm the progesterone 
action was receptor-mediated. Moreover, various amounts of hPR-A or hPR-B 
expression vectors (from 0.25 ng to 4 ng) were co-transfected into JEG-cells with 
the hU plasmid and treated with 0.1 nM of progesterone to see the effects of 
exogenous expression of PRs on the hGnRH upstream promoter activity.
To determine whether the receptor-mediated progesterone action was dose- 
related, 3 p.g of hU and 1 ^g of hPR-A or hPR-B co-transfected JEG-3 cells were 
treated with various concentrations of progesterone (from 0.01 nM to 100 nM) for 
20 h. The lysates were assayed for luciferase activities. The pCMV p- 
galactosidase plasmid was also co-transfected into JEG-3 cells with test 
construct(s) in each experiment to correct for variations in transfection efficiency.
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3.3. Examine the effects o f coactivators SRC-1 and CBP on hPR-A and hPR-B 
mediated progesterone regulation of the hGnRH upstream promoter activity in 
JEG-3 cells.
To determine the effects of exogenously expressed coactivators SRC-1 or 
CBP on the hPR-A and hPR-B mediated progesterone action, 1 pg of SRC-1 or 
CBP were transfected into JEG-3 cells with the hU plasmid and hPR-A or hPR-B, 
respectively. The cells were then treated with progesterone and harvested for 
luciferase activity assay. Transfection efficiency was corrected by co-transfection 
of pCMV p-galactosidase plasmid with test constructs in each experiment.
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MATERIALS AND METHODS
Cell culture
Human placental choriocarcinoma cells (JEG-3), mouse neuronal cells (GT1- 
7), and human kidney cells (293) were purchased from American Type Culture 
Collection (ATCC, Rockville, MD). JEG-3 and GT1-7 cells were maintained in 
Dulbecco’s Modified Eagle’s Medium (DMEM; Sigma, St. Louis, MO) 
supplemented with 10% fetal bovine serum (FBS). The 293 cells were grown in 
Modified Eagle Medium (MEM; Sigma, St. Louis, MO) with 10% FBS. The cells 
were passaged or frozen when 80% confluence. For hormone treatment studies, 
the cells were cultured in serum and phenol red free DMEM or MEM (Life 
Technologies, Gaithersburg, MD) during treatment.
Construction of plasmids
TKU was made by inserting a 272-bp fragment (-994 to -723) containing all 
the four footprinted elements derived from the full length 5’-flanking region of the 
hGnRH gene into a herpes simplex thymidine kinase (TK) minimal 
promoter/luciferase reporter vector, pT109luc (Fig. 4). The individual or combined 
sequences of the four elements were generated by PCR using the following 
specific primers:
A2: 5’-TATCTCGAGAAGCACTCATTACAATAG-3’,
B1: 5-GTCGACAATAAATGTAATAAGAGTAATGGT-3’,
C1: 5’-GTCGACTTTCAGCCTAGGGGTAAATTAG-3’;
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D1: 5’-C AGTCG ACG AG AG ATTTAAATAAG-3’,
C2: 5’-TATCTCGAGCTAATTTACCCCTAGGCT-3’,
D2: 5’-TATCTCGAGCCATCTTATTTAAATCTC-3’,
A1: 5’-GGTCGACCTACCTGGTTAAAAGCT-3’,
E2: 5’-TATCTCGAGGCATTTAGTGAGCATTCG-3’, 
and cloned into the pT109luc vector to produce hGnRH upstream promoter 
element/TK-luciferase constructs (TKU432, TKU43, TKU4, TKU321, TKU32, and 
TKU1. Kindly prepared by Kei-Li Yu, University of Hong Kong, Hong Kong, 
China) (Fig.4). For element knockout studies (deletion of FP3 or FP2), the 
construct TKU421 and TKU431 were generated by annealing the 
oligonucleotides 5’-
CCAAGCTTCACTAAATGCCGGGGGGATGGGATCTTTGACTATT-3’ and A2, 
5 -
CCCT CG AGCAACCATTACT CTTATTACATTTATTCCT GTAATAGT CAAAG AT C- 
3’ and A1, and then cloned into pT109luc vector, respectively. For block mutation 
of FP4 or FP3 and estrogen responsive element studies, the plasmid hU5a-m4, 
hU5a-m3, and mERE were made by annealing the sense oligonucleotides 5’- 
CCAAGCTTAATGGCAGGACTGCCCGAATATAATGGCATTAAGAGAGATTTAA 
ATAA-3’, 5’-
CCAAGCTTGCCGCTCTGTCGGGCCCGCGCTCGAAACCTTTGACTATTACAG 
GTTTC-3’, 5 -
CCAAGCTTTGTAAATAACCATAGTTGAATTGCACCTCTGGGGTGGAAC-3’, 
with antisense oligonucleotide 5’-CCCTCGAGCTTAAGTGCAGCCATTAAAACC-
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3’, and cloned into promoter-less pxp2-luc vector, respectively. All constructs 
were transformed into DH5 E.coli competent cells and positive clones were 
confirmed by restriction mapping, Southern blot analysis, and DNA sequencing. 
For serial deletion study, a set of 5’ end deletion in the hGnRH upstream 
promoter/pxp2-luc constructs (hU5, hU5a, hU5b, hU5c, hU5d, and hU5e) was 
generated by Exonucleaselll/Mung Bean Nuclease deletion (Kindly prepared by 
Kei-Li Yu, University of Hong Kong, Hong Kong, China).
Preparation of plasmid DNAs
Plasmid DNAs were transformed into DH1 E.coli bacteria host and amplified 
in 500 ml Luria-Bertani medium (5 g Yeast, 10 g Trypton, 5 g NaCI, pH7.5, and 
50 |ig/ml of Ampicilin) in shaking incubator at 37°C, 200-rpm overnight. Bacteria 
cells were harvested by centrifugation at 4°C, 6,000 rpm for 10 min. Plasmid 
DNAs were prepared by CONCERT High Purity Plasmid Maxiprep System (Life 
Technologies, Gaithersburg, MD) according to the manufacture’s instruction with 
minor modification. DNA concentration was determined spectrophotometrically 
by absorbance at 260 nm and verified by comparison with known mass lambda 
DNA standards on agarose gel.
Transient transfection assay and luciferase activity assay
Transfection assays were carried out in triplicate by the calcium phosphate 
coprecipitation method without glycerol shock (Sambrook et al., 1989). The 
amounts of DNA in each experiment are given in the figure legends. All
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transfections included a  pCMV p-galactosidase construct (Clontech, San 
Francisco, CA) as an internal control for transfection efficiencies. A  constant 
amount of transfected DNA was maintained by the addition of nonspecific 
plasmid DNA. Cells weres plated at a density of 2-5 x 105 cells per 60-mm dish 
one day before transfection. Transfected plates were washed three times with 1 x 
PBS and fresh serum an d phenol red free medium was applied with or without 
treatment. Cells were furtlher incubated for 20 h before harvesting by scraping the 
cells into 200 pi of lysis b uffer (1% Triton-X 100; 25 mM glycylglycine, pH7.8; 15 
mM MgS04; 4 mM EGTA; and 1 mM dithiothreitol). After centrifugation at 4°C, 
14,000 rpm for 5 min, lucfferase activity (de Wet et al., 1987) was measured on a 
Lumat LB9501 luminometer (EG&G Berthold) by mixing 100 pi o f the cell 
extracts, 360 pi of luciferase assay buffer (25 mM glycylglycine, pH 7.8; 15 mM 
MgS04; 4 mM EGTA; 15 mM KPB, pH 7.8; 1 mM dithiothreitol; and 2 mM ATP), 
and 100 pi of luciferin buffer (2 mM D-luciferin [Sigma, St. Louis, MO] and 25 mM 
glycylglycine, pH7.8) (Wondisford et al., 1989). To correct protein amount for 
luciferase activity, protein concentrations of the lysates were determined by BCA 
Protein Assay kit (PIERCXE, Rockford, IL). Portion of the harvested cell extract 
was used to quantify p-galactosidase synthesis by colorimetric assay at 405 nm.
Isolation of nuclear extract
To prepare JEG-3 cell nuclear extract for EMSA, the JEG-3 cell pellets were 
resuspended in five packed cell volumes of ice-cold buffer A (10 mM HEPES- 
NaOH, pH 7.9; 10 mM KCI; 1.5 mM MgCl2 ; 1 mM dithiothreitol; 50 pg/ml
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phenymethylsulfonylfluoride [PMSF]) and incubated on ice for 10 min. The cell 
nuclei were separated from cytoplasmic supernatant by centrifugation at 4°C, 
12,500 rpm for 25 min, and resuspended in 0.25 packed cell volume of ice-cold 
buffer C (20 mm HEPES-NaOH, pH 7.9; 10 mM KCI; 1.5 mM MgCI2; 1 mM 
dithiothreitol, 50 pg/ml PMSF, 0.25 mM EDTA, and 25% glycerol) and 
homogenized in Dounce homogenizer. After rocking at 4°C for 30 min, the nuclei 
extract was harvested and the supernatant was dialyzed against 250 ml buffer D 
(20 mM HEPES-NaOH, pH 7.9; 100 mM KCI; 1 mM dithiothreitol, 50 pg/ml 
PMSF, 0.2 mM EDTA, and 20% glycerol). Then, the nuclei extract solution was 
collected and saved at -80°C for subsequent EMSA. Protein concentration was 
measured by BCA Protein Assay kit (PIERCE, Rockford, IL).
Electrophoretic mobility shift assay (EMSA) and supershift assay
For the EMSA, annealed wild-type oligonucleotides containing sequences of 
the four footprinted elements (FP1: -876 to -851, 5’-
AATAAATGTAATAAGAGTAATGGTTG-3’; FP2: -919 to -896, 5’-
TTTCAGCCTAGGGGTAAATTAG-3’; FP3: -960 to -940, 5 -
GAG AGATTTAAATAAG AT G-3’; FP4: -987 to -968, 5’-
CTCACTAAATGCCGGGGG-3’), as well as the putative ERE of the hGnRH 
upstream promoter (pERE: -824 to -784, 5’-
TGTGTAAATAACACGTCCACGGTTGCACCTCTGGGGTGGAACAT-3’) were 
labeled with [y-32P]ATP (6,000 Ci/mmol; NEN, Boston, MA) by using T4 
polynucleotide kinase. Binding reactions were carried out in 10 mM Tris-HCI (pH
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glycerol, 3 pg of nuclear extract or 7.3 pmol of recombinant ERa protein 
(Panvera, Madison Wl), and 20,000 cpm of labeled probe in total volume of 25 pi. 
Reaction mixtures were incubated at room temperature for 10 min, loaded onto 
8% polyacrylamide gel (acrylamide-bisacrylamide [37.5:1], 0.25x TBE), and 
electrophoresed for 2 h at 200 V in cold room. Gels were pre-run for 30 min in
0.25x TBE. Then, the gels were dried and subjected to autoradiography. For 
competition reactions, the reactions were preincubated with the specified amount 
of excess unlabeled oligonucleotide at room temperature for 20 min before the 
addition of probe. Supershift assays were performed by incubating the reactions 
with 1 pi of Oct-1 antibody (sc-232x, Santa Cruz Biotechnology Inc., Santa Cruz, 
CA) or rabbit IgG control at room temperature for 1 h before the addition of 
probe.
RNA isolation
To isolate cytoplasmic RNA for RT-PCR, cells were rinsed twice in cold 1x 
PBS and scraped into 0.5 ml of ice-cold lysis buffer (10 mM Tris-HCI, pH7.4; 3 
mM CaCh; 2 mM MgCfe; 0.5 mM dithiothreitol; 0.3 M Sucrose; 0.15% Triton X- 
100). The cell lysis was then layered over 0.35 ml of cushion buffer (10 mM Tris- 
HCI, pH7.4; 1.5 mM MgCh; 0.4 M Sucrose) in 1.5 ml microcentrifuge tube on ice. 
After centrifugation for 10 min at 5000 g, 4°C, 0.5 ml of the supernatant was 
transferred to a fresh microcentrifuge tube and mixed with 58 pi of 10x SET (10% 
SDS; 50 mM EDTA; and 100 mM Tris-HCI, pH7.4), 12 pi o f proteinase K (10
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mg/ml), and 17 pi of 5 M NaCl. The mixture was incubated at 45°C for 1 hour, 
followed by extraction with phenol/chloroform and precipitation with 100% ethanol 
at -20°C overnight. RNA was recovered by centrifugation for 20 min at 14,000 
rpm, 4°C, air-dried and resuspended in 20 pi RNase free water. The quantity of 
RNA was determined by measuring the absorbance of 260 and 280 nm. The 
integrity of RNA obtained and absence of chromosomal DNA were verified by 
running 2% agarose gel.
RT-PCR
RT-PCR was used to determine the presence of hER a and hERf3, as well as 
PR in JEG-3 cells. For first-strand cDNA synthesis, approximate 10 pg of 
cytoplasmic RNA were reverse transcribed in a final volume of 30 pi. The 
reaction mixture included 1.0 x RT buffer (50 mM Tris-HCI, pH 8.3; 75 mM KCI; 
and 3 mM MgCI2), 0.1 mg/ml BSA, 1.0 mM dithiothreitol, 0.05 pg/pl oligo-dT-(12- 
18), 0.5 mM dNTP, 1 U/pl RNAsin, and 200 U M-MLV reverse transcriptase (Life 
Technologies, Gaithersburg, MD). The reaction mixture was incubated at 42°C 
for 2 min, followed by incubation at 37°C for 1.5 hours, and then quenched on 
ice.
For PCR amplification, 5 pi of the first-strand cDNA was amplified in a final 
volume of 25 pi. The reaction mixture included 1 x PCR buffer (20 mM Tris-HCI, 
pH 8.4; 50 mM KCI; and 5 mM MgCI2), 0.25 mM dNTP, 1.5 mM MgCI2, 1.25 U 
Taq polymerase (Life Technologies, Gaithersburg, MD), and the following 
primers: hERa sense, 5’-GAGACATGAGAGCTGCCAAC-3’ and antisense, 5’-
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
46
CCAAGAGCAAGTTAGGAGCA-3’; hERp sense 5’-
AGTATGTACCCTCTGGTCACAGCG-3’ and antisense 5’-
CCAAAT GAGGG ACC ACACAGC AG-3’; hPR sense, 5’-
GATTCAGAAGCCAGCCAGCCAG-3’ and antisense 5’-
AGTTGCCTCTCGCCTAGT-3’. Amplification conditions were 35 cycles of 
denaturation at 94°C for 1 min, annealing at 55°C for 30 sec, and extension at 
72°C for 2 min, followed by a final extension at 72°C for 10 min. The PCR 
products were run on 2% agarose gels containing ethidium bromide, and 
visualized using a UV illuminator.
Western blot
Total cell protein extracts were prepared by lysis o f cell monolayers with 
protein lysis buffer (1% Triton X-100; 25 mM glycylglycine, pH 7.8; 15 mM 
MgSC>4 ; 4 mM EGTA; and 1 mM dithiothreitol). Protein concentration was 
measured by BCA Protein Assay kit (PIERCE, Rockford, IL). Equal amounts of 
total cellular protein extracts (10-20 pg) were separated by 8% sodium dodecyl 
sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and blotted onto a 
cellulose nitrate membrane (Amersham LIFE SCIENCE, Arlington Heights, IL). 
Proteins were visualized using ECL detection system (Amersham LIFE 
SCIENCE, Arlington Heights, IL) according to manufacture’s instruction with 
modification. Briefly, the protein-blotted membrane was incubated in 10% BSA 
blocking buffer at 4°C overnight, followed by incubation with 1st antibody (Oct-1 
[sc-8024x], PR-A/B [sc-810], and PR-A [sc-811] mouse monoclonal antibody
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from Santa Cruz Biotechnology Inc., Santa Cruz, CA) at 4°C for 1 h. The 
membrane was then washed three times by 0.4% Tween20/PBS for 15 min and 
detected by 2nd antibody (mouse Ig, horseradish peroxidase-linked whole 
antibody). After washing three times with 0.3% and 0.1% Tween20/PBS for 15 
min, the membrane was developed and exposed to XAR-5 film (Kodak).
Data analysis
All transient transfection assays were carried out in triplicate and repeated at 
least three times on independent experiments. Data were standardized for 
protein concentration and p-galactosidase activity, and represented as relative 
light unit (x1,000) and mean values + SEM. Student’s t test was used to compare 
differences between mean values of two different treatments. Data for dose 
response studies were analyzed for statistical significance using one-way 
ANOVA. When the F test for the ANOVA reached statistical significance, 
differences between specific mean values were assessed by least-significant- 
difference (LSD) test. Differences of P < 0.05 were accepted as statistically 
significant.
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RESULTS
Part I: Multiple cis-regulatory elements mediate hGnRH upstream promoter 
activity in the tissue-specific expression of hGnRH gene in JEG-3 cells.
1. Four cis-regulatory elements confer the tissue-specific expression o f the 
full hGnRH upstream promoter in JEG-3 cells.
To determine whether the four footprinted elements can act as cis-regulatory 
elements to confer tissue-specific expression of the hGnRH upstream promoter 
in human placenta, the sequence containing these four elements (-994 to -723) 
was placed upstream to the TK/luciferase reporter (TKU in Fig. 6). The human 
placental JEG-3 cells were used as in vitro placenta model, while GT1-7 cells as 
hypothalamic neurons and human kidney 293 cells as non-reproductive tissue. 
The TKU construct, TK vector and the 5’ full-length hGnRH upstream 
promoter/luciferase construct (hU in Fig. 6) were transfected into JEG-3, GT1-7, 
and 293 cells, respectively. As shown in Fig. 6, the promoter activity conferred by 
these four elements alone (TKU) was similar to that of the full-length hGnRH 
upstream promoter. In contrast, the TK promoter itself had very low activity in 
JEG-3 cells. All tested constructs were not active in GT1-7 and 293 cells. These 
results indicate that the four footprinted elements, but not the TK promoter, 
confer tissue-specific expression of the TKU in JEG-3 cells.
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Fig. 6. The four footprinted elements in the hGnRH upstream promoter are 
responsible for the tissue-specific expression in JEG-3 cells. Three micrograms 
of hU, TKU, or TK were co-transfected with 2 fig of pCMV p-galactosidase into 
JEG-3, 293, and GT1-7 cells, respectively. The cells were harvested after 20 h 
and lysates were assayed for p-galactosidase and luciferase activities. Data were 
standardized to p-galactosidase activities as a control for transfection efficiency. 
Each bar represents the mean + SEM of luciferase activity, which is shown as 
relative light units. *, P < 0.05 as compared to TK; n/s, not significant (by 
Student’s t test).
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2. Footprinted element 4 (FP4) is the most important for the tissue-specific 
expression of the hGnRH gene in JEG-3 cells.
To determine how these four elements contribute to the tissue-specific 
expression of the hGnRH upstream promoter in JEG-3 cells, different 
combinations of these four elements were generated by PCR with specific 
primers (Fig. 4, as described in Materials and Methods) and then cloned into 
TK/luciferase reporter. These deletion constructs were transfected into JEG-3 
cells for luciferase activity assay. As showed in Fig. 7, deletion of FP4 
dramatically decreased the luciferase activity by nearly four-fold (P < 0.05), while 
deletion of FP1, FP2, or FP3 only caused about two-fold decrease of luciferase 
activity, respectively (P < 0.05). Further deletion of FP3 or FP2 only caused 
slightly additional decrease of the luciferase activity (TKU21 and TKU43 in Fig. 
8). Deletion of three of the four elements from either side (FP4, FP3, FP2, or 
FP3, FP2, FP1) resulted in an additional decrease of less than 10% (TKU1 and 
TKU4 in Fig. 9). Taken together, deletion of FP4 significantly decreased the 
luciferase activity (TKU321 in Fig. 10). Further deletion of the other elements 
(FP3 or FP3 and FP2) only caused slightly additional decrease of the luciferase 
activity (TKU21 and TKU1 in Fig. 10). On the other hand, deletion of FP1 caused 
a 50%, FP2 45%, and FP3 35 % loss of the luciferase activity (TKU432, TKU431, 
and TKU421 in Fig. 10,), respectively. These results clearly indicated that all four 
elements are required to confer the full hGnRH upstream promoter activity in 
JEG-3 cells. However, the FP4 is the most important for the hGnRH upstream 
promoter activity in JEG-3 cells.
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Fig. 7. Single-element deletion analysis of the four footprinted elements in the 
tissue-specific expression of hGnRH gene in JEG-3 cells. Three micrograms of 
hGnRH deletion constructs (TKU321, TKU421, TKU431, and TKU432), four- 
element construct (TKU), or TK and 2 pg of pCMV p-galactosidase were co­
transfected into JEG-3 cells, respectively. After 20 h, the cells were harvested 
and lysates were assayed for p-galactosidase and luciferase activities. Data were 
standardized to p-galactosidase activities and shown as relative light units. Each 
bar represents the mean + SEM. *, P < 0.05 as compared to TKU (by one-way 
ANOVA and LSD).
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Fig. 8. Two-element deletion analysis of the four elements in the tissue-specific 
expression of hGnRH gene in JEG-3 cells. Three micrograms of hGnRH deletion 
constructs (TKU21 and TKU 43), TKU, or TK and 2 jig o f pCMV p-galactosidase 
were co-transfected into JEG-3 cells, respectively. After 20 h, cell lysates were 
assayed for p-galactosidase and luciferase activities. Data were standardized to 
p-galactosidase activities and shown as relative light units. Each bar represents 
the mean + SEM. *, P < 0.05 as compared to TKU (by one-way ANOVA and 
LSD).
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Fig. 9. Three-element deletion analysis of the four footprinted elements in the 
tissue-specific expression of hGnRH gene in JEG-3 cells. Three micrograms of 
hGnRH deletion constructs (TKU1 and TKU 4), TKU, or TK and 2 pg o f pCMV p- 
galactosidase were co-transfected into JEG-3 cells, respectively. After 20 h, cell 
lysates were assayed for p-galactosidase and luciferase activities. Data were 
standardized to p-galactosidase activities and shown as relative light units. Each 
bar represents the mean + SEM. *, P < 0.05 as compared to TKU (by one-way 
ANOVA and LSD).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
54
IFP41FP31FP21FP11-----1 TK ILUCI TKU
|FP3|FP2|FPTl r~TK~
|FP2lFP1| fTK
[fpTI pfK
IFP4 |FP3I FP2l------------TTK
|FP4|FP3|
i?P4T^FP2|FP1| PfK
IFP41FP3 K^ ^TfpTI fTK
LUC] TKU321
LUC TKU21
LUCl TKU1
LUC] TKU432
LUCl TKU43
LUC] TKU4
LUC] TKU421
LUC] TKU431
Relative Percent of TKU
Fig. 10. Comparison of luciferase activities between various hGnRH upstream 
promoter elements)/TK-luciferase constructs. Relative luciferase activities from 
various hGnRH deletion constructs and TKU transfected JEG-3 cells were 
assayed and represented as the mean + SEM of relative percent of TKU’s 
luciferase activity. *, P < 0.05 as compared to TKU (by one-way ANOVA and 
LSD).
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3. Serial deletion analysis supports the roles of the -four elements in the 
tissue-specific expression of the hGnRH gene in JEG -3 cells.
To confirm the interactive roles of the four elements- in the tissue-specific 
expression of the hGnRH upstream promoter in JEG -3 cells, transient 
transfections were performed in JEG-3 cells with a set o f 5’ end deletion of the 
hGnRH upstream promoter/luciferase constructs. As shovwn in Fig. 11, deletion 
of the hGnRH upstream promoter to -991 bp retained m ost o f the full upstream 
promoter activity. Deletion to -935 bp (FP4 and FP3 w e re  removed) resulted in 
significant decrease of the full upstream promoter activity. However, further 
deletion to -880 bp (FP4, FP3, and FP2 were removed) on ly resulted in a slightly 
additional decrease in the upstream promoter activity. Whe=n deletion was up to — 
827 bp (all four elements were removed), the hGnRH upstream promoter activity 
was dramatically decreased to a level more than six-fold below  that of the four- 
element construct (hU5a). Additional deletion to -775 bp made no further 
significant change of the luciferase activity. Thus, the results of serial deletion 
analysis further confirmed that the four cis-regulatory elements are essential for 
the hGnRH upstream promoter activity in JEG-3 cells.
In addition, mutational analysis was performed to provide further evidence for 
the importance of FP4 in the hGnRH upstream promoter activ ity in JEG-3 cells. 
Using PCR with specific primers (as described in Materials and Methods), FP4 
and FP3 were replaced by unrelated sequences and clor&ed into promoter-less 
luciferase reporter. This two mutant constructs were then transfected into JEG-3 
cells for luciferase activity analysis. As shown in Fig. U2, mutation of FP4
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Fig. 11. Serial 5’ deletion analysis of hGnRH upstream promoter activity in JEG-3 
cells. All 5’ deletion constructs shown extend to -202 bp in their 3’ extent. The 
hGnRH upstream transcription start site is shown as bent arrow. Three 
micrograms of test plasmids and 2 pg of pCMV p-galactosidase were co­
transfected into JEG-3 cells and cells harvested after 20 h. Lysates were 
assayed for p-galactosidase and luciferase activities. Data were standardized to 
P-galactosidase activities as a control for transfection efficiency. Each bar 
represents the mean + SEM of luciferase activity, which is shown as relative light 
units. *, P < 0.05 as compared to hU (by one-way ANOVA and LSD), n/s, not 
significant (by Student’s t test).
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Fig. 12. Mutational analysis of FP4 and FP3 elements. FP4 and FP3 block 
mutation constructs (hU5a-m4 and hU5a-m3) were made by PCR as described 
in Materials and Methods. Three micrograms of test plasmids and 2 p.g of pCMV 
p-galactosidase were co-transfected into JEG-3 cells. After 20 h incubation, cell 
lysates were assayed for p-galactosidase and luciferase activities. Data were 
standardized for p-galactosidase activities as a control for transfection efficiency. 
Each bar represents the mean + SEM of luciferase activity, which is shown as 
relative light units. *, P < 0.05 as compared to TKU (by one-way ANOVA and 
LSD).
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resulted in two-fold decrease, while mutation of FP3 only resulted in slightly 
additional decrease of the luciferase activities similar as that of FP1/FP2 
construct (hU5b). These results further support the important role of FP4 in the 
hGnRH upstream promoter activity in JEG-3 cells. Taken together, all the four 
elements are involved in the tissue-specific expression of the hGnRH gene in 
JEG-3 cells, while the FP4 element is the most important
4. POU-homeodomain protein Oct-1 is involved in the DNA-protein 
interaction of FP4 in the hGnRH upstream promoter.
Sequence analysis revealed that the four elements are short AT-rich, 
suggesting the possible binding of transcriptional factor POU-homeodomain 
protein Oct-1. To determine whether Oct-1 is expressed in our JEG-3 cells, 
western blot assay was performed with specific antibody against Oct-1 protein. 
As shown in Fig. 13, the expression of Oct-1 was detected in our JEG-3 cells 
with higher concentration in nuclear extract. Subsequently, gel mobility shift 
assay was conducted to examine the DNA-protein interaction between the four 
elements and nuclear extract from JEG-3 cells. As expected, all of the four 
elements bound with JEG-3 nuclear extract (Fig. 14, lane 2, 7, 12, and 17). Also, 
the bound protein(s) can be competed out with 500-fold of excess unlabeled 
corresponding oligonucleotides (Fig. 14, lane 3, 8, 13, 18), indicating the specific 
DNA-protein interaction. Furthermore, supershift assay using Oct-1 antibody was 
carried out to see if Oct-1 protein is directly involved in the DNA-protein 
interaction. As shown in Fig. 14 (lane 19), only FP4 DNA-protein complex was
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Nuclear extract Whole cell lysate
Fig. 13. Expression of POU homeodoamin protein Oct-1 in JEG-3 cells. Western 
blot was performed to determine the presence of Oct-1 in JEG-3 cells. Ten 
micrograms of nuclear extract or whole cell lysate from JEG-3 cells were loaded 
on to 8% SDS-PAGE gel and detected with specific antibody against Oct-1 
protein.
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Fig. 14. Oct-1 binding within FP4. EMSAs were performed with [y-32P]ATP 
labeled oligonucleotides corresponding to footprints 1 to 4 (FP1, lanes 1-5; FP2, 
lanes 6-10; FP3, lanes 11-15; FP4, lanes 16-20) and 3 pg of nuclear extract from 
JEG-3 cells (lanes 2-5, 7-10, 12-15, 17-20). Competition assays were conducted 
with 500-fold of excess unlabeled corresponding oligonucleotides (lanes 3, 8, 13, 
18). Supershift assays were conducted in the presence of either Oct-1 specific 
antibody (lanes 4, 9, 14, 19) or nonspecific rabbit IgG (lanes 5, 10, 15, 20). The 
arrows on the left show the gelshift bands, while on the right is supershift band.
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supershifted by Oct-1 antibody but not by rabbit IgG (Fig. 14, lane 20). Other 
elements (FP1, FP2, FP3) were not supershifted by Oct-1 antibody (Fig. 14, lane 
4, 9, 14). These results indicated that Oct-1 binds to FP4 element and may 
function as a transcriptional regulatory protein in the hGnRH upstream promoter 
in JEG-3 cells.
Part II: Estrogen receptor a  and p mediated estrogen regulation of the 
hGnRH upstream promoter activity in JEG-3 cells.
1. Detection of human estrogen receptor a  (hERa) and p (hERP) mRNAs in 
JEG-3 cells.
Although the presence of both ERa and ERp in human placenta has been 
demonstrated (Brandenberger et al., 1997; Moore et al., 1998), the human 
placental JEG-3 cells have been reported to be deficient in ER (Chatterjee et al., 
1989). To determine whether our JEG-3 cell line expresses hERa and hERp, RT- 
PCR was performed on cytoplasmic RNAs from JEG-3 cells with specific primers 
for hERa and hERp (as described in Materials and Methods). The RT from MCF- 
7 cells, which are known for hERa and hERp expression, and ER cDNA plasmids 
were used as positive control. Also, cyclophilin primers were applied as internal 
control. As shown in Fig. 15, hERa and hERp transcripts were amplified from 
hERa and hERp cDNAs as well as MCF-7 cells, but not from our JEG-3 cells. 
These results indicated that our JEG-3 ceils do not express hERa and hERp. 
Thus, hERa and hERp expression vectors will be transfected into JEG-3 cells in 
later estrogen treatment studies.
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Fig. 15. Detection of hERa and hERp mRNAs in JEG-3 cells by RT-PCR. 
Cytoplasmic RNAs were prepared from JEG-3 and MCF-7 cells. RT-PCR was 
then performed with specific primers for hERa and hERp. Cyclophilin was used 
as internal control. The hERa and hERp cDNA plasmids, MCF-7 sample were 
used as positive control. The amplified cyclophilin, hERa and hERp products are 
shown as arrows.
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2. Both hERa and hERp mediate inhibitory effects of estradiol on the 
hGnRH upstream promoter activity in JEG-3 cells.
The ERa mediated estradiol down-regulation of the hGnRH upstream 
promoter activity has been reported previously (Dong et al., 1996). Because 
hERa and hERp possess distinctive transactivational domains, I co-transfected 
hERa or hERp expression vectors with the hGnRH upstream promoter/luciferase 
construct (hU) into JEG-3 cells to determine the differential effect of hERa and 
hERp mediated estradiol regulation of the hGnRH upstream promoter activity in 
JEG-3 cells. The cells were then treated with 10 nM of 17p-estradiol (E2) with or 
without 1 p.M of antiestrogen ICI164.384 (ICI). As shown in Fig. 16, the luciferase 
activity had little change with the treatment of estradiol and/or IC1164,384 when 
without co-transfection o f hERa and hERp, supporting the deficiency of ER in 
JEG-3 cells. When hERa was co-transfected into JEG-3 cells, as expected 
estradiol treatment significantly decreased the luciferase activity. Further, 
addition of IC1164,384 abolished the inhibitory effect of estradiol on the hGnRH 
upstream promoter activity, while IC1164,384 alone made little change on the 
luciferase activity. Co-transfection of hERp displayed the similar inhibitory effect 
as hERa did, but in a less extent. These results indicate that both hERa and 
hERp mediate inhibitory effects of 17p-estradiol on the hGnRH upstream 
promoter activity in JEG-3, while hERp acts less potent than hERa does.
3. The hERa- and hERp-mediated inhibitory effects of estradiol on the 
hGnRH upstream promoter activity are dose-dependent.
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Fig. 16. ER-mediated estradiol regulation of hGnRH upstream promoter activity. 
The cells were transfected with 3 ^g of hU and 2 ^g of pCMV p-galactosidase, 
with or without 1 jig of hERa or hERp. Then, the cells were treated for 24 h with 
various combinations of vehicles, E2 (10 nM) and ICl (1 jaM) as indicated. 
Lysates were assayed for p-galactosidase activity and luciferase activity as 
described in Materials and Methods. Each bar represents the mean + SEM and 
standardized luciferase activities are shown as relative light units. *, P < 0.05 as 
compared to control (no E2) (by Student’s t test).
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To confirm that hERa and hERp mediate the estradiol effects on the hGnRH 
upstream promoter, 3 pg of hU and various amounts of hERa or hERp were co­
transfected into JEG-3 cells in the presence of 10 nM of 17p-estradiol. As 
expected (Fig. 17, hERa), increasing exogenous expression of hERa resulted in 
decreasing luciferase activity, with maximal estradiol action was obtained at 1 pg 
of transfected hERa. Transfection of additional more hERa (2 or 4 pg) did not 
result in further decrease. On the other hand, hERp displayed maximal inhibitory 
effect at 0.25 pg transfected (Fig. 17, hERp). Increasing transfected hERp (up to 
4 pg) resulted in less inhibitory effect, but still mediated the down-regulation of 
17p-estradiol on the hGnRH upstream promoter activity in JEG-3 cells. These 
different effects may be due to the differential transactivation of hERa and hERp.
To determine whether the estradiol effect on the hGnRH upstream promoter 
is dose-dependent or not, JEG-3 cells were co-transfected with 3 pg of hU 
construct and 1 pg of hERa or hERp expression vector, and then treated with 
various concentrations of 17p-estradiol. As shown in Fig. 18, estradiol down- 
regulated the hGnRH upstream promoter activity in a dose-dependent manner. 
Compared to that o f hERa, hERp mediated the effect in a less extent. For both 
hERa and hERp, 17p-estradiol produced a significant decrease in the luciferase 
activity at concentration as low as 0.01 nM, with a maximal effect at 
concentration of 100 nM. Thus, both hERa and hERp mediate dose-dependent 
response of the hGnRH upstream promoter to 17p-estradiol, while hERp in a less 
extent.
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Fig. 17. Dose-dependent effect o f exogenous hERa or hERp expression on 
hGnRH upstream promoter activity in JEG-3 cells. JEG-3 cells were transfected 
with 3 pg of hU plus various amounts of hERa or hERp expression vector as 
indicated. After treatment with 10 nM E2 for 24 h, cell lysates were assayed for 
luciferase activities as described in Materials and Methods. Each bar represents 
the mean + SEM and luciferase activities are shown as relative light units. *, P < 
0.05 as compared to control (No ER) (by one-way ANOVA and LSD).
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Fig. 18. Dose-dependent response of hGnRH upstream promoter to estradiol 
treatment. Transient transfections were performed in JEG-3 cells with 3 pg of hU 
plus 1 pg of hERa or hER(3. After 24 h treatment with various concentrations of 
estradiol as indicated, lysates were assayed for luciferase activities as described 
in Materials and Methods. Each bar represents the mean + SEM and luciferase 
activities are shown as relative light units. *, P < 0.05 as compared to control (no 
17p-estradiol) (by one-way ANOVA and LSD).
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4. The hERa- and hERp-mediated regulatoiry effects of estrogen isoforms 
on the hGnRH upstream promoter activity im JEG-3 cells.
Estrogen has multiple isoforms, such as estrone, estradiol, and estriol that 
have been found to be present in the human placenta. It is of interesting to see 
the effects of these estrogen isoforms on the h*GnRH upstream promoter activity. 
For this purpose, JEG-3 cells were co-transf^ected with the hGnRH upstream 
promoter/luciferase construct (hU) and hERa or hERp expression vector, and 
then treated with estrone, estradiol, or estrio l for 24 h, respectively. The ceil 
lysates were analyzed for luciferase activity. A s  shown in Fig. 19, without ER co­
transfected, these estrogen isoforms made little  change of the luciferase activity. 
When hERa co-transfected, estradiol and esttriol, but not estrone significantly 
decreased the luciferase activities (P < 0.05). 'While co-transfection of hERp, ail 
these estrogens resulted in significant loss «of luciferase activity (P < 0.05). 
However, estradiol displayed more potent inhibitory effect via hERa than hERp, 
while estriol showed similar effect via hERa or hERp.
5. interactive effects of hERa and hERp on the hGnRH upstream promoter 
activity in JEG-3 cells.
It has been reported that ERa and ERp can interact each other to form 
heterodimer and thus modulate transactivation~al activities each other (Paech et 
al., 1997). To determine whether hERa sand hERp modulate each other in
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Fig. 19. Effects of different estrogens on hGnRH upstream promoter activity in 
JEG-3 cells. JEG-3 cells were transfected with 3 pg of hU and 1 pg of hERa or 
hERp. The cells were then treated for 24 h with 10 nM of various vehicles, 
estrone, estradiol, or estriol. Lysates were assayed for luciferase activities as 
described in Materials and Methods. Control without any treatment. Each bar 
represents the mean + SEM and luciferase activities are shown as relative light 
units. *, P < 0.05 as compared to no ER; n/s, not significant (by Student’s t test).
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Fig. 20. Interactive effects of hERa and hERp on hGnRH upstream promoter 
activity in JEG-3 cells. JEG-3 cells were transfected with 3 pig of hU and various 
amount of hERa and hERp as indicated. The cells were then treated with 10 nM 
of 17p-estradio! for 24 h. Lysates were assayed for luciferase activities as 
described in Materials and Methods. Each bar represents the mean + SEM for 
luciferase activities shown as relative light units. *, P < 0.05 as compared to 
control (no ER transfected) (by one-way ANOVA and LSD).
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mediating the estradiol effect on the hGnRH upstream promoter, various 
amounts of hERa and/or hERp as indicated in Fig. 20 were co-transfected with 
hU into JEG-3 cells. The cells were then treated with 10 nM of 17p-estradiol for 
24 h before luciferase assay. When 1 jag of hERa was transfected with 
increasing amount of hERp (from 0.25 to 4 fig), the inhibitory effect of 17p- 
estradiol on the promoter activity was lessened to the maximal at 2 ng of hERp 
co-transfected. On the other hand, the down-regulation of estradiol on the 
hGnRH upstream promoter was enhanced with increasing amount of hERa (from
0.25 to 4 |ig) and 1 fig of hERp co-transfected. These results indicate that hERa 
and hERp can modulate each other in mediating the estradiol effect on the 
hGnRH upstream promoter activity in JEG-3 cells.
To confirm the co-transfection of hERa and/or hERp into JEG-3 cells, RT- 
PCR was performed on the cytoplasmic RNAs prepared from hERa and/or hERp 
transfected JEG-3 cells. As shown in Fig. 21, hERa was detected only in hERa 
transfected cells, but not in hERp as well as no ER transfected cells. Also, hERp 
was only found in hERp transfected but not in hERa and no ER transfected cells.
6. Analysis of negative and positive estrogen responsive elements in the 
hGnRH upstream promoter.
Previous studies in our laboratory have demonstrated a negative estrogen 
responsive element (-991 to -935) and a positive (-827 to -730) estrogen 
responsive element in the hGnRH upstream promoter region. To further confirm
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Fig. 21. Determination of hERa and hERp transfection in JEG-3 cells by RT- 
PCR. Cytoplasmic mRNAs were prepared from 3 jig of hU, 1 pg of hERa and/or 
hERp, co-transfected JEG-3 cells. RT-PCR was then conducted with specific 
primers for hERa and hERp. Cyclophilin was used as internal control.
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these findings, mutational studies on the negative and positive estrogen 
responsive elements were conducted. Using PCR, the negative estrogen 
responsive element was replaced by two unrelated sequences (Fig. 22A) and 
then cloned into the promoter-less luciferase reporter, pxp2luc. The mutant 
constructs and wild type plasmid were transfected into JEG-3 cells with hERa or 
hER|3. As shown in Fig. 22B, replacement of the negative estrogen responsive 
element with unrelated sequence partially abolished ERa- or ERp-mediated 
responsiveness of hGnRH upstream promoter to 17p-estradiol treatment. The 
positive estrogen responsive element containing putative ERE was also replaced 
by unrelated sequence using PCR (Fig. 23A). The mutant element was 
subsequently cloned into pxp2luc and transfected with hERa or hERp into JEG-3 
cells, followed by 17p-estradiol treatment. As shown in Figure 23B, mutation of 
the positive estrogen responsive element partially abolished ERa-mediated 
stimulatory effect, but no significant change for ERp.
To explore the protein(s) bound to the putative ERE which located within the 
positive estrogen responsive element, EMSA and supershift with anti-ERa 
antibody have been performed previously, and showing no supershift of the 
element-protein complex. In the present study, EMSA was conducted with [y- 
32P]ATP labeled the putative ERE and recombinant hERa protein to further 
determine whether ER protein directly binds to this putative ERE. As shown in 
Fig. 24, hERa protein did not bind to the putative ERE, indicating that ER protein 
does not directly involve in the DNA-protein interaction.
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wE4: 5’-CCAAGCTTCCGAATGCTCACTAAATGCCGGGGGTTTATTAAGAGAGATTTAAATAA-3’ 
mE4: 5’-CCAAGCTTAATGGCAGGACTGCCCGAATATAATGGCATTAAGAGAGATTTAAATAA-3’
wE3: 5’-CCAAGCTTTATTAAGAGAGATTTAAATAAGATGGGATCTTTGACTATTACAGGTTTC-3’ 
mE3: 5’-CCAAGCTTGCCGCTCTGTCGGGCCCGCGCTCGAAACCTTTGACTATTACAGGTTTC-3’
A
Wt mE4 mE3 Wt mE4 mE3
ERa ERp
B
Fig. 22. Mutational analysis of negative estrogen response element in the 
hGnRH upstream promoter. A. The sequences of wild type negative estrogen 
response element and corresponding mutations. B. JEG-3 cells were co­
transfected with 1 pg of hERa or hERp and 3 pg of wild type negative estrogen 
response element construct Wt (hU5a, -991/-202), mutational construct mE4 and 
mE3, respectively. The cells were then treated with or without 10 nM of 17p- 
estradiol for 24 h. Lysates were assayed for luciferase activities. Data are 
standardized to p-galactosidase activity (co-transfected as control for transfection 
efficiency) and expressed as percent of control (no Ez treatment). *, P < 0.05 as 
compared to Ez treated Wt (by Student’s t test).
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Putative ERE: 5’-CCAAGCTTTGTAAATAACACGTCCACGGTTGCACCTCTGGGGTGGAAC-3’ 
Mutant ERE: 5’-CCAAGCTTTGTAAATAACCATAGTTGAATTGCACCTCTGGGGTGGAAC-3*
A
180 - |
Wt mERE Wt mERE
ERa ERp
B
Fig. 23. Mutational analysis of positive estrogen response element in the hGnRH 
upstream promoter. A. Sequences for wild type putative ERE and mutated ERE. 
B. Transient transfections were performed in JEG-3 cells with 1 |jg of hERa or 
hERp and 3 ^g of wild type putative ERE construct Wt (hU5d, -827/-202) or 
mutant ERE construct mERE. After 24 h treatment with 10 nM of 17p-estradiol, 
lysates were assayed for luciferase activities. Data are shown as percent of the 
control (no E2 treatment). *, P < 0.05 as compared to E2 treated Wt; n/s, no 
significance (by Student’s t test).
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Fig. 24. The hERa protein does not bind to the putative ERE in the hGnRH 
upstream promoter. EMSA was performed with [y-32P]ATP labeled 
oligonucleotides corresponding to the putative ERE (-824 to -784) in the hGnRH 
upstream promoter and 7.3 pmol of hERa protein. Competition assays were 
conducted with 500-folk excess of the unlabeled probe.
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Part III: Progesterone receptor A and B mediated progesterone regulation 
of the hGnRH upstream promoter activity in JEG-3 cells.
1. Detection of human progesterone receptor A (hPR-A) and B (hPR-B) in 
JEG-3 cells.
The expression of hPR has been reported in the human placenta (Chibbar et 
al., 1995; Shanker et al., 1997). To determine whether our JEG-3 cell line 
expresses hPR, RT-PCR was performed on the cytoplasmic RNAs from JEG-3 
cells with specific primers for hPR (as described in Materials and Methods). The 
RT from MCF-7 cells, which are known for hPR expression, and hPR-A and hPR- 
B expression vectors were used as positive control. As shown in Fig. 25A, hPR 
transcript was amplified from our JEG-3 cells. Since hPR-A and hPR-B are 
differentially translated from the same mRNA transcript, western blot assay with 
specific antibodies against hPR-A/B and hPR-B was conducted. As shown in Fig. 
25B, both hPR-A and hPR-B were detected from our JEG-3 cells. These results 
indicate that our JEG-3 cells express hPR-A and hPR-B protein.
2. The hPR-A mediates stimulatory effect of progesterone on the hGnRH 
upstream promoter in JEG-3 cells.
The stimulatory effect of progesterone (P4) on the hGnRH upstream promoter 
has been demonstrated in JEG-3 cells with or without hPR-B expression vector 
transfected (unpublished data in our lab). To determine the action of hPR-A in 
mediating the effect of progesterone on the hGnRH upstream promoter, 1 pg of 
hPR-A was co-transfected with the hGnRH upstream promoter/luciferase 
reporter (hU) into JEG-3 cells and treated with various vehicles, 0.1 nM P4 and 5
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Fig. 25. Detection of hPR expression in JEG-3 cells by RT-PCR and Western 
blot. A. Cytoplasmic mRNAs were prepared from JEG-3 and MCF-7 cells. RT- 
PCR was then performed with specific primers for hPRs and cyclophilin (internal 
control). The hPR-A and hPR-B expression plasmids as well as MCF-7 sample 
were used as positive control. B. Western blot was conducted with specific 
antibodies against hPR-A/B and hPR-B as described in Materials and Methods.
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Fig. 26. PR-mediated progesterone stimulatory effect on hGnRH upstream 
promoter. JEG-3 cells were transfected with 3 pg of hU and 2 pg of pCMV pgal, 
with or without 1 pg of hPR-A or hPR-B. The cells were then treated for 24 h with 
various combinations of vehicle, P4 (0.1 nM) and RU486 (5 pM) as indicated. 
Lysates were assayed for luciferase activity as described in Materials and 
Methods. Each bar represents the mean + SEM and luciferase activities are 
shown as relative light units. *, P  < 0.05 as compared to control (no treatment) 
(by Student’s t test).
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pM RU486 as indicated in Fig. 26. As expected, P4 treatment increase the 
luciferase activity, while exogenous expression of hPR-B further enhanced the 
stimulatory effect of P4. This stimulatory effect was abolished by addition of 
RU486, a progesterone antagonist, which had no significant effect on the hU. 
Co-transfection of hPR-A exhibited similar stimulatory effect as hPR-B did but 
with a less potent. Thus, hPR-A also mediates a stimulatory effect of 
progesterone on the hGnRH upstream promoter in JEG-3 cells.
To confirm the hPR-A mediated stimulatory effect of P4 on the hGnRH 
upstream promoter, various amounts of hPR-A expression vector and 3 pg of hU 
were co-transfected into JEG-3 cells and treated with 0.1 nM of P4. As shown in 
Fig. 27, increasing amount of exogenous hPR-A transfection resulted in augment 
of luciferase activity. The maximal luciferase activity reached was at 2 pg of hPR- 
A. Further addition of hPR-A could not increase the luciferase activity any more. 
As a comparison, various amounts of hPR-B were co-transfected into JEG-3 
cells with hU and treated with 0.1 nM of P4. The results showed that hPR-A 
mediated the stimulatory effect of P4 in a less potent than that of hPR-B at all 
amount of DNA transfected. Taken together, hPR-A mediates stimulatory effect 
of progesterone on the hGnRH upstream promoter activity but with a less potent 
as compared to that of hPR-B.
3. Dose-dependent response of the hGnRH upstream promoter to 
exogenous hPR-A and hPR-B mediated progesterone treatment.
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Fig. 27. Dose-dependent effect of exogenous hPR-A and hPR-B expression on 
the hGnRH upstream promoter activity in JEG-3 cells. JEG-3 cells were 
transfected with 3 pg of hU plus various amounts of hPR-A or hPR-B expression 
vector as indicated. The cells were thesn treated for 24 h with 0.1 nM P4. Lysates 
were assayed for luciferase activity. Two microgram of pCM y p-galactosidase 
was co-transfected to control transfection efficiency. Results are represented as 
relative light units with the mean + SEBVI. *, P < 0.05 as compared to control (no 
PR) (by one-way ANOVA and LSD).
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Fig. 28. Dose-dependent response of hGnRH upstream promoter to 
progesterone treatment. Transient transfections were performed in JEG-3 cells 
with 3 pg of hU and 1 pg of hPR-A or hPR-B. After 24 h treatment with various 
concentrations of P4 as indicated, lysates were assayed for luciferase activity. 
Each bar represents the mean + SEM for luciferase activity which is shown as 
relative light units. *, P < 0.05 as compared to control (no progesterone) (by one­
way ANOVA and LSD).
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To determine whether the responsiveness of the hGnRH upstream promoter 
to hPR-A and hPR-B mediated progesterone treatment is dose-dependent, hPR- 
A or hPR-B and hU co-transfected JEG-3 cells were treated with various 
concentrations of progesterone (P4, from 0.01 nM to 100 nM). As shown in Fig. 
28, progesterone at the concentration of 0.1 nM produced maximal effect on the 
promoter activity in both hPR-A and hPR-B transfected cells. However, when 
increasing the concentration of progesterone, little change in luciferase activity 
was observed in hPR-A transfected cells, while decreasing luciferase activity was 
displayed in hPR-B transfected cells. Therefore, hPR-A and hPR-B mediated 
stimulatory effects of progesterone on the hGnRH upstream promoter are dose- 
dependent, but also is biphasic in hPR-B transfected cells.
4. Coactivators SRC-1 and CBP upregulate hPR-A and hPR-B mediated 
stimulatory effect of progesterone on the hGnRH upstream promoter.
It has been reported that steroid receptor coactivator-1 (SRC-1) and CREB 
binding protein (CBP), independently or synergistically, enhance PR dependent 
transcription in a variety of cell lines (Onate ert al., 1995; Lundblad et al., 1995; 
Smith et al., 1996). In this study, SRC-1 and CBP expression vectors were co­
transfected with the hU plasmid and hPR-A or hPR-B into JEG-3 cells to see 
whether exogenous expression of coactivator(s) could modulate hPR-mediated 
hGnRH upstream promoter activity. As shown in Fig. 29, co-transfection of SRC- 
1 or CBP significantly increased the luciferase activity in hPR-A or hPR-B 
transfected cells, while SRC-1 showed stronger effect than that of CBP. When
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4r / / / / / /
hU (jig) 3 3 3 3 3 3 3 3 3 3
PR-A(ng) 1 1 1 1 - - - -
PR-B (ng) 1 1 1 1
SRC-1 (jig) 1 - 1 - 1 - 1
CBP (jig) - 1 1 - - 1 1
Fig. 29. Coactivator SRC-1 and CBP upregulate PR-mediated action on hGnRH 
upstream promoter activity in JEG-3 cells. The cells were co-transfected with 
different constructs as indicated and treated with 0.1 nM of progesterone for 24 
h. The lysates were assayed for luciferase activity. Data are represented as 
percent of control (hU). *, P < 0.05 as compared to no coactivator transfected (by 
one-way ANOVA and LSD).
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both SRC-1 and CBP were simultaneously co-transfected, the PR-mediated 
progesterone stimulatory effect on the upstream promoter was further increased. 
These results indicated that SRC-1 and CBP, independently or synergistically, 
upregulate hPR-A and hPR-B mediated stimulatory effect of progesterone on the 
hGnRH upstream promoter in JEG-3 cells.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
86
DISCUSSION
1. The application of the human placental JEG-3 cell line as in vitro human 
placenta model.
To study the hGnRH gene expression and regulation in the human placenta, 
in vivo placenta, primary placental cell culture, and placental derived cell lines 
could be used as the study models. Due to the extremely low level of the GnRH 
produced in the placenta, it is not applicable to detect the changes in the GnRH 
level in the in vivo placenta. Also, the in vivo study of the hGnRH promoter 
activity could only be conducted in transgenic animals (Wolfe et al., 1996). 
Furthermore, the gene expression is under complex control, and therefore it is 
unlikely to be able to investigate single factor in the in vivo circumstances. 
Primary cell culture of the human placenta provides an alternative source for 
studying the hGnRH gene expression and regulation in the placenta. The 
advantage is that the primary placental cell culture might be more closely 
resemble to the in vivo placenta. The disadvantage, however, is that once 
removed from the in vivo placenta, the cells face a constantly changing 
environment which is difficult to control for gene expression study. The difficulty 
to obtain large amount of placentas also limits its application in the present study.
The available immortal cell lines have made gene expression and regulation 
studies practical. For GnRH promoter activity studies, the human placental JEG- 
3 cells and mouse GT1-7 cells have been widely used as in vitro models for 
placenta and neuron (Radovick et al., 1991; Wierman et al., 1992; Weiner et al.,
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1993; Wetsei et al., 1993; Kepa et al., 1996; Dong et al., 1993). JEG-3 cell line Is 
a human choriocarcinoma cell cloned from the Woods strain of the Erwin-Turner 
tumor in its 387th passage in hamster check pouch (Kohler et al., 1971). 
Similarities between normal and tumor placental cells have also been reported 
(Elston, 1979). This cell line can release human chorionic gonadotropin (hCG), 
human chorionic somatomammotrophin (hCS), and progesterone. It is also be 
able to transform steroid precursors to estrone and estradiol. Furthermore, the 
presence of the hGnRH and hGnRH receptor mRNAs in this cell line has been 
demonstrated (Dong et al., 1993; Yin et al., 1998). Although the presence of 
estrogen receptor and progesterone receptor in the human placenta has been 
reported (Younges et la., 1981; Kim et al., 1985; Chibbar et al., 1995; 
Rossmanith et al., 1997; Shanker et al., 1997 and 1998), only PR has been 
detected in our JEG-3 cells.
The mouse GT1-7 cell line was developed by targeting the SV-40 large T 
antigen to the hGnRH expressing hypothalamic neurons with the rat GnRH 
promoter (Mellon et al., 1990). This cell line can express prepro-GnRH mRNA 
and biosynthesize, process, and release pro-GnRH-derived peptides into the 
medium (Wetsei et al., 1991). GT1-7 cells also maintain the pulsatile pattern of 
the hGnRH secretion that is critical for successful reproduction (Wetsei et al., 
1992). Thus, GT1-7 cell line is a suitable hypothalamic neuron model for GnRH 
studies.
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2. The application of luciferase reporter gene in promoter activity studies.
The luciferase reporter gene has provided a sensitive, convenient, and cost- 
effective approach to study the transcriptional activity of cloned DNA sequences 
after introducing these elements into appropriate target cells. The mechanism of 
the luciferase catalysis reaction is: luciferase + luciferin + ATPMg2+ <-> 
iuciferase*luciferyl-AMP + PPi, luciferase*luciferyl-AMP + O2 -> luciferase + 
oxyluciferin + AMP + CO2 + rty (de Wet et al., 1987). Since mammalian cells do 
not contain any kind of luciferase, this reporter gene, in theory, is only limited by 
the “background noise” of the instrument. Light emission is directly proportional 
to the amount of luciferase produced in the transfected cells.
In the present study, two luciferase reporter genes were applied. One is 
promoter-less pxp2-luc, in which the hGnRH upstream promoter was cloned 
upstream luciferase gene to drive the expression o f luciferase. Another is herpes 
simplex thymidine kinase (TK) minimal promoter/luciferase reporter pT109-luc, in 
which the hGnRH upstream cis-regulatory elements were cloned upstream the 
truncated TK promoter to regulate its activity.
3. The application of transient transfection assay in promoter activity 
studies.
In this study, calcium phosphate co-precipitation method was used for 
transient transfection assay because of the simplicity and low cost of this 
method. Also, its transfection efficiency of 10-20% in JEG-3 cells was high 
enough for the present study. Blank plasmid DNA, such as pCDNA, was used to
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keep the total transfected DNA equal for each transfection. To correct the 
variation in transfection efficiency, a pCMV (3-galactosidase plasmid was co­
transfected into the cells with test plasmids. Further, the protein concentrations of 
the cell lysates were measured to normalize the protein amount for luciferase 
assay.
For steroid hormone treatment studies, it is essential to use phenol red free 
and fetal bovine serum (FBS) free medium to limit the influence of other 
stimulants and endogenous steroid hormones within cells. Since 10% FBS was 
critical for transfection in our JEG-3 cells, the regular medium supplemented with 
10% FBS was used after transfection. The cells were then culture in phenol red 
free and FBS free medium with or without treatment for additional 20-24 h. Thus, 
the cells may still contain endogenous steroids at effective level during the study, 
resulting slightly higher background luciferase activities for non-treated cells.
4. The tissue-specific hGnRH upstream promoter activity is directed by 
multiple cis-regulatory elements.
Complex mechanisms have been evolved to ensure proper spatial and 
temporal expression of genes in differentiated tissues. In part, this control is 
achieved at the transcriptional level, so that regulatory regions containing 
multiple cis-acting sequence elements control both the level of gene expression 
and its restriction to appropriate cell types. The expression of the hGnRH gene 
has been found only in the hypothalamic neurons and a few non-hypothalamic 
tissues such as reproductive tissue, indicating the tissue-specific expression of
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this gene. The identification of a second promoter (upstream promoter) that 
mainly used in reproductive tissue but not in neural cells further supports this 
concept (Dong et al., 1993). This observation has also been confirmed by the 
other group (Kepa et al., 1996). Recently, a 325-bp region between -1048 and -  
723 has been demonstrated to be involved in directing the activity of the hGnRH 
upstream promoter in the human placental JEG-3 cells. DNase I footprinting and 
gel mobility assays indicated four specific elements in this region that bind to 
nuclear extracts only from the human placental JEG-3 cells but not from the 
hypothalamic neural GT1-7 cells (Dong et al., 1997). These results strongly 
suggest that these four footprinted elements may be involved in the tissue- 
specific expression of the hGnRH gene in the human placental JEG-3 cells. In 
the present study, we demonstrated that the element 4 (FP4, -987/-968) is the 
most important for the hGnRH upstream promoter activity in JEG-3 cells. 
However, FP4 alone only produced about 40% of TKU activity (Figure 10). No 
single element can confer the full promoter activity. Therefore, all four elements 
are required to confer the tissue-specific expression of the hGnRH gene in JEG-3 
cells, indicating that multiple components may be involved in the regulation of 
tissue-specific expression of the hGnRH gene in the placenta.
In the rat GnRH gene promoter, several groups (Whyte et al., 1995; Kepa et 
al., 1992 and 1996; Clark et al., 1995; Eraly et al., 1995) have reported the 
presence of potent neural-specific enhancer as well as cis-acting regulatory 
elements. This neural-specific enhancer is located in the distal promoter region 
between —1863 and —1571 in the rat GnRH promoter, while the cis-acting
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regulatory elements are crowded in the proximal region of 173 bp 5’ of the 
transcriptional start site (Whyte et al., 1995; Eraly et al., 1995). Results of studies 
by using GT1-7 neural cell line have demonstrated that the hGnRH gene also 
possesses a neural-specific enhancer (Kepa et al., 1996) but its location in the 
proximal promoter region (-535 to -47) is different from that of the rat neural- 
specific enhancer. Further studies have indicated that the sequences of the 
proximal region of GnRH genes are conserved across species and consist of 
multiple cis-acting elements that are necessary for basal and regulated GnRH 
gene transcription (Eraly et al., 1995). A nucleotide sequence comparison of the 
GnRH promoter between rat and human revealed that there is high homology in 
the proximal promoter region between -1 to -551 of hGnRH and —1 to -424 of rat 
GnRH (Kepa et al., 1996). In contrast, the hGnRH promoter region (-1131 to - 
551) has little similarity in the distal promoter region when compared to that of rat 
(-1031 to -424). It is of interesting that the hGnRH gene upstream promoter is 
located in this region. Thus, the results of the present study also suggest a 
species-specific difference in the structural organization of cis-acting promoter 
elements used to confer the tissue-specific expression o f the hGnRH gene in the 
human placenta.
The presence of putative DNA-binding sites for transcription factors on the 5’ 
flanking region of the hGnRH gene have been reported (Kepa et al., 1996). Since 
POU homeodomain protein Oct-1 is expressed in a variety of tissues and cell 
types (Sturm et al., 1987) including placental JEG-3 cells and neuronal GT1-7 
cells, it is believed that Oct-1 participates in tissue-specific gene expression by
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interaction with either other transcription factors (Voss et al., 1991; Poellinger et 
al., 1992) or tissue-specific co-activators (Luo et al., 1992; Strubin et al., 1995). 
In the rat GnRH promoter, it has been reported that binding o f Oct-1 to the 
promoter elements is required for the tissue-specific expression in the 
hypothalamic cell-line, GT1-7 (Eraly et al., 1998). Close examination of the four 
footprinted elements from the hGnRH upstream promoter revealed short AT-rich 
sequences, all containing the octamer-like sequence TAAAT, which is most likely 
the target of POU homeodomain proteins. Although the octamer-like motifs within 
these four elements are somewhat deviated from the octamer consensus 
sequence ATGCAAAT, Oct family proteins are known to interact with AT-rich 
sequences with relaxed specificity (Bendall et al., 1993). In the present study, we 
demonstrated that Oct-1 only binds to the FP4 (5-CTCACTAAATGCCGGGGG- 
3’) which shows a four of eight match to the octamer consensus sequence, but 
not the FP3 (5'-GAGATTTAAATAAG-3’) which represents a six of eight match, 
as well as other elements, suggesting other POU homeodomain transcription 
factors may interact with these elements. Furthermore, western blot assay has 
demonstrated the expression of Oct-1 protein in our JEG-3 cells. Therefore, Oct- 
1 may participate in the placenta-specific expression of the hGnRH gene by 
direct binding to FP4 and interacting with the other tissue-specific proteins and/or 
transcriptional factors.
5. Estrogen receptor a  and p mediated estrogen regulation of the hGnRH 
upstream promoter activity in JEG-3 cells.
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It is known that estradiol and progesterone are among the most important 
steroid hormones in regulating the hypothalamic GnRH production. The finding 
that GnRH-secreting GT1 neuronal cells contain ER and PR has indicated that 
the actions of steroid hormones are mediated by their receptors (Roy et al., 1999; 
Kepa et al., 1996). The human placenta also contains both ER and PR and 
steroid hormones exert their effects in a receptor-mediated manner in the 
placenta (Younges et al., 1981; Chibbar et al., 1995; Shanker et al., 1997 and 
1998; Rossmanith et al., 1997). Furthermore, the placenta is a major source to 
produce estrogen and progesterone during gestation. Since the hGnRH 
upstream promoter is the major one functioning in the placenta, the present study 
was focused on the regulation of the hGnRH upstream promoter activity in JEG-3 
cells. A luciferase reporter-transient transfection system was used in the human 
placental JEG-3 cells to investigate the receptor-mediated effects of estradiol and 
progesterone on the hGnRH upstream promoter activity.
Recent studies have shown that human estrogen receptor has two major 
subtypes, estrogen receptor a and p, with similarities and differences (Kuiper et 
al., 1997; Paech et al., 1997). ERp has the DNA binding domain that is almost 
identical to the homologous ERa, implying that both ERa and ERp might share 
the same DNA response element. They can also form heterodimer complex, 
suggesting their possible cross-talking (Sumito et al., 1998). However, ERa and 
ERp have different activation function region and ligand binding domain that 
might result in the distinctive transactivational mechanisms (Paech et al., 1997). 
Evidence has indicated that each receptor subtype may perform specific
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biological functions. In tissues where both receptors are co—expressed, however, 
the two receptors could play redundant roles: physically interact to form 
heterodimers or act as targets of independent signaling pathways. Thus, the 
presence of two receptor isoforms increases the complexity of ER-mediated 
effects on estrogen responsive genes. Using RT-PCR, th e  expression of hERa 
and hERp in the human placenta has been reported (Brand«enberger et al., 1997; 
Moore et al., 1998). JEG-3 cells are known to be deficient itn ERa. I herein using 
RT-PCR demonstrated that our JEG-3 cells are also deficient in ERp. Thus, ERa 
and ERp expression vectors were transfected into JEG -3 cells to create ER- 
positive cells for estrogen regulation studies.
Previous studies in our laboratory have shown an ER«x-mediated inhibitory 
effect of estradiol on the hGnRH upstream promoter activity in JEG-3 cells (Dong 
et al., 1996; Chen et al., 2000). The present studies demonstrated that ERp also 
mediated a negative effect of estradiol on the upstream promoter, but to a lesser 
extent and decreased inhibitory effect when increasing exogenous expression of 
ERp. In contrast, ERa mediates a more potent repressive effect and increased 
inhibition when exogenously overexpressed in JEG-3 ceBls. This was further 
supported by the result from co-transfection of both ERa a n d  ERp with various 
ratios (Figure 20), suggesting ERa and ERp could modulate each other. Because 
the placenta contains both ERa and ERp proteins, it is possible they co-express 
in the same kind of cell and interact each other. However, it is not clear how 
exactly ERa and ERp interact inside the JEG-3 cells, forrming heterodimer or 
acting as targets of independent signaling pathways. Treatment with various
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estrogen isoforms also resulted in different responses between ERa and ERp 
transfected cells. These differences may be due to the distinctive 
transactivational mechanisms of ERa and ERp (Paech et al., 1997), especially in 
the AF-1 and AF-2 activation function regions. In addition, other groups 
demonstrated negative regulation of rat and human GnRH promoter activity 
(Wierman et al., 1992) and positive regulation of hGnRH promoter activity 
(Radovick et al., 1991) by estrogen. Such controversial results may be due to 
different promoter regions to be studied as well as tissue and species 
differences.
Furthermore, a negative (-991 to -935) and a positive (-827 to -730) estrogen 
responsive element in the hGnRH upstream promoter functioning in JEG-3 cells 
have been demonstrated in our laboratory (Chen et al., 2000). The positive 
element also contains a putative ERE, but its DNA-protein complex in supershift 
assay could not be super-shifted by anti-ER antibody. In the present study, 
mutations of the two elements abolished the responses to estradiol, further 
confirmed their roles in the estradiol regulation of the hGnRH upstream promoter 
in JEG-3 cells. However, gel-shift assay showed no binding of the putative ERE 
with recombinant ERa protein, suggesting that ER does not directly interact with 
the putative estrogen responsive element. This is further supported by other 
studies on the transcriptional repression of the GnRH gene by estrogen 
(Wierman et a!., 1992; Kepa et al., 1994). They were also unable to detect ER 
binding to their negative response element even though the DNA-binding domain 
of the ER was required for estrogen-mediated repression.
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The mechanism of ER-mediated regulation of gene transcription is generally 
thought to be direct interaction of ER protein with its palindromic consensus DNA 
sequences (ERE). However, increasing evidence has shown that steroid 
hormone receptor-mediated negative regulation, unlike the positive regulation, 
does not usually occur through direct interaction with consensus DNA sequence. 
For example, protein-protein interactions are thought to be important for inhibition 
of AP-2 stimulated activity by the SV40 large tumor antigen (Mitchell et al., 1989), 
inhibition of prolactin promoter activity by the estrogen receptor binding to Pit 1 
(Adler et al., 1988), ligand-dependent repression o f the erythroid transcription 
factor GATA-1 by ER (Blobel et al., 1995), and repression of IL-6 gene 
expression by ER binding to NF-IL6 and NF-kB (Ray et al., 1997). The similar 
mechanism of repression is also postulated for functional antagonism between 
Fos/Jun and estrogen via the interference at the non-receptor binding AP-1 site 
that involves formation of heterodimeric complexes between ER and Fos/Jun 
(Doucas et al., 1991; Paech et al., 1997). Alternatively, different trans-acting 
factors may compete for binding at the same DNA sequences as described for 
glucocorticoid receptor interference at cAMP element binding sites in the human 
a-subunit gene (Akerblom et al., 1988). In addition, trans-acting factors may 
interfere directly with normal transcriptional initiation apparatus as suggested by 
studies of negative regulation by thyroid hormone of the glycoprotein hormone a- 
subunit gene (Chatterjee et al., 1989) and rat growth hormone gene (Crone et al., 
1990) by binding to region adjacent to the TATA box, as well as transcriptional 
repression of the ovine FSHp gene by estrogen (Miller et al., 1996). Also,
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negative regulation may occur via protein interaction with DNA sequences within 
the gene itself thus resulting in premature termination of the primary transcript 
elongation as in regulation of the human thyroid stimulating hormone p-subunit 
gene (Wondisford et al., 1989). Finally, recent evidence have demonstrated the 
possible presence of plasma membrane ER that mediate the nongenomic action 
of estrogen through signal transduction pathways (such as MAP kinase) even 
though it usually mediates acute effect (Levin, E.R., 1999; Shaul, P.W., 2000). 
Therefore, all these examples demonstrate that the classical concept of ER 
regulating genes following an obligatory step of DNA binding is no longer 
generally applicable. Results from the present studies and other groups 
(Wierman et al., 1992; Kepa et al., 1994) indicated that ER most likely binds to 
other transcription factors that are in contact with the negative and positive 
response elements to regulate hGnRH gene transcription. Future studies into the 
transcription factor(s) that bind to the response element(s) and interact with ER 
will aid in the elucidation of transcriptional repression of the hGnRH gene by 
estrogen.
6. Progesterone receptor A and B mediated progesterone regulation of the 
hGnRH upstream promoter activity in JEG-3 cells.
Progesterone can either stimulate or inhibit GnRH production in the 
hypothalamus depending on different physiological circumstances through direct 
or indirect actions on the GnRH neurons. The demonstration of the presence of 
progesterone receptor in the GnRH neurons suggests that progesterone may
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directly exert its actions on the GnRH gene expression through its specific 
receptor. In the placenta, Petraglia et al. (1990) showed that progesterone 
decreased the release o f immunoreactive GnRH from cultured human placental 
cells and this inhibitory effect was completely reversed by RU486, a specific 
receptor antagonist, suggesting a receptor-mediated action. Recent studies in 
our laboratory demonstrated a progesterone receptor-mediated positive effect of 
progesterone on the hGnRH upstream promoter activity in the human placental 
JEG-3 cells. Because the human PR exists as two isoforms, hPR-B and hPR-A, 
with distinctive transactional domains, the different effects of progesterone on the 
GnRH gene expression may be due to the receptor-mediation by different 
isoforms. Using RT-PCR, the presence of PR mRNA has been detected in the 
human placenta as well as in our JEG-3 cells. However, due to PR-A and PR-B 
forms are resulted from mRNA alternative splicing, RT-PCR cannot distinguish 
between PR-A and PR-B. Shanker et al. (1998) using EMSA demonstrated the 
presence of only PR-A but not PR-B in the first trimester and term placenta. 
Using western blot assay with specific antibodies against hPR-A/B or hPR-B, 
both forms of PR were detected in our JEG-3 cells in the present study.
Although in most cells hPR-A does not activate transcription but functions as 
a strong trans-dominant repressor of hPR-B (Vegeto er al., 1993), the result in 
the present study showed that both forms of PR mediate stimulatory effect of 
progesterone on the hGnRH upstream promoter activity in JEG-3 cells. To study 
the roles of PR isoforms in directing progesterone effect on the upstream 
promoter, hPR-A and hPR-B expression vectors were introduced into JEG-3 cells
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in this study. However, JEG-3 cells contain endogenous PR-A and PR-B 
although their concentrations are not determined yet. Thus, endogenous PRs 
may have somewhat influence on the luciferase activity. Furthermore, PRs 
generally exert their actions through binding to the consensus PRE 
(progesterone responsive element) on the cis-regulatory region of target genes. 
Most of the studies on the PR regulated transcription are based on the reporter 
construct that containing PRE. Although the direct DNA binding of PR to 
nonconsensus elements has been demonstrated in the proximal rat GnRH 
promoter (Kepa et al., 1996), the progesterone responsive element(s) have not 
been fully clarified in the hGnRH upstream promoter.
Coativators, SRC-1 and CBP, have been demonstrated to increase PR 
dependent transcription in a variety of cell lines by using PRE-containing reporter 
constructs (Onate et al., 1995; Lundblad et al., 1995; Smith et al., 1996). Our 
functional transfection studies showed that SRC-1 and CBP, independently and 
synergistically, enhance both hPR-A and hPR-B mediated hGnRH upstream 
promoter activity in JEG-3 cells, indicating SRC-1 and CBP may be also involved 
in the PR dependent transcription of hGnRH gene in the placenta.
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CONCLUSIONS
Multiple cis-regulatory elements are involved in the tissue-specific expression 
of hGnRH gene in JEG-3 cells. No single element is sufficient to confer full 
transcriptional activity. However, the sequence between -987 and -968 (FP4) is 
the most important for the hGnRH upstream promoter activity in JEG-3 cells, and 
the POU homeodomain protein Oct-1 involves in its DNA-protein interaction, 
indicating that Oct-1 may be an important factor in regulating the tissue-specific 
expression of hGnRH in the placenta.
Both ERa and ERp mediate inhibitory effect of estrogen on the hGnRH 
upstream promoter activity in JEG-3 cell with a dose-dependent manner, and can 
modulate each other’s regulation of transcription. However, ERa and ERp exhibit 
different ability to direct the effects of estrone, estradiol, and estriol on the 
hGnRH upstream promoter activity in JEG-3 cells. Moreover, the sequence 
between -991 and -935 mediates negative estrogen response, while the 
sequence between -827 and -730 mediates positive estrogen response in the 
hGnRH upstream promoter. However, ER protein does not directly involve in 
DNA binding.
Progesterone increases the hGnRH upstream promoter activity in JEG-3 cells 
in a PR-A and PR-B dependent manner. This stimulatory effect can be enhanced 
by coactivators, SRC-1 and CBP, independently and synergistically. However, 
PR-A and PR-B exert their actions in mediating the hGnRH upstream promoter 
activity in JEG-3 cells with different extent.
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